Nikolić, Katarina

Link to this page

Authority KeyName Variants
orcid::0000-0002-3656-9245
  • Nikolić, Katarina (242)
Projects
Synthesis, Quantitative Structure and Activity Relationship, Physico-Chemical Characterisation and Analysis of Pharmacologically Active Substances Ministry of Education, Science and Technological Development, Republic of Serbia, Grant no. 451-03-68/2020-14/200161 (University of Belgrade, Faculty of Pharmacy)
Sinteza, kvantitativni odnosi između strukture/osobina i aktivnosti, fizičko-hemijska karakterizacija i analiza farmakološki aktivnih supstanci COST Action Epigenetic Chemical Biology CM1406
EU COST Action CM 1103 Development of molecules with antiinflammatory and cardioprotective activity: structural modifications, modelling, physicochemical characterization and formulation investigations
Modeling and Numerical Simulations of Complex Many-Body Systems Application of the EIIP/ISM bioinformatics platform in discovery of novel therapeutic targets and potential therapeutic molecules
EU COST Action CA 15135 EU COST Action CM 1207
Translational Research Innovation-Pharma (TRIP) COST Action CA18133
COST Actions CA18240 and CA18133 Else Kroner-Fresenius-Stiftung
Fraunhofer-Projektgruppe fur Translationale Medizin und Pharmakologie (TMP) Plants and synthetic bioactive products of new generation
Action LIONS Vaincre le Cancer association Amedis
And through Grant Agreement with University of Belgrade - "VINˇCA" Institute of Nuclear Sciences - National Institute of the Republic of Serbia No: 451-03-4 Angelini Pharma
Brain Korea (BK21) PLUS programme Chiesi Foundation
College of Pharmacy-Glendale, Midwestern University, USA Cost Action 18133
COST Action Adher´n Rise CA18240 COST-Action CA18133 ERNEST: European Research Network on Signal Transduction
COST action CM1103 COST Action CM1406
COST-Action CM1406 “Epigenetic Chemical Biology (EpiChemBio)” COST-Action CM1406 “Epigenetic Chemical Biol- ogy” (EpiChemBio)

Author's Bibliography

Theoretical and experimental study of bilastine ionization

Popović Nikolić, Marija; Popović, Gordana; Oljačić, Slavica; Nikolić, Katarina

(Institute for Information Technologies, University of Kragujevac, Serbia, 2023-09)

TY  - CONF
AU  - Popović Nikolić, Marija
AU  - Popović, Gordana
AU  - Oljačić, Slavica
AU  - Nikolić, Katarina
PY  - 2023-09
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5045
AB  - The protolytic equilibria of bilastine were studied experimentally and theoretically. The
pKa values were determined potentiometrically at a constant ionic strength (0.1 M NaCl) and
temperature 25 °C. Energy calculation of the optimized structures of the equilibrium forms was
performed at the B3LYP/6-31G (d,p) level of the Density Functional Theory (DFT). The results of
the theoretical study helped to define the ionization profile of bilastine and to assign the
experimentally determined pKa values to the corresponding ionizable groups.
PB  - Institute for Information Technologies, University of Kragujevac, Serbia
C3  - 2nd International Conference on Chemo and Bioinformatics ICCBIKG 2023, BOOK OF PROCEEDINGS
T1  - Theoretical and experimental study of bilastine ionization
SP  - 427
EP  - 430
DO  - 10.46793/ICCBI23.427PN
ER  - 
@conference{
author = "Popović Nikolić, Marija and Popović, Gordana and Oljačić, Slavica and Nikolić, Katarina",
year = "2023-09",
abstract = "The protolytic equilibria of bilastine were studied experimentally and theoretically. The
pKa values were determined potentiometrically at a constant ionic strength (0.1 M NaCl) and
temperature 25 °C. Energy calculation of the optimized structures of the equilibrium forms was
performed at the B3LYP/6-31G (d,p) level of the Density Functional Theory (DFT). The results of
the theoretical study helped to define the ionization profile of bilastine and to assign the
experimentally determined pKa values to the corresponding ionizable groups.",
publisher = "Institute for Information Technologies, University of Kragujevac, Serbia",
journal = "2nd International Conference on Chemo and Bioinformatics ICCBIKG 2023, BOOK OF PROCEEDINGS",
title = "Theoretical and experimental study of bilastine ionization",
pages = "427-430",
doi = "10.46793/ICCBI23.427PN"
}
Popović Nikolić, M., Popović, G., Oljačić, S.,& Nikolić, K.. (2023-09). Theoretical and experimental study of bilastine ionization. in 2nd International Conference on Chemo and Bioinformatics ICCBIKG 2023, BOOK OF PROCEEDINGS
Institute for Information Technologies, University of Kragujevac, Serbia., 427-430.
https://doi.org/10.46793/ICCBI23.427PN
Popović Nikolić M, Popović G, Oljačić S, Nikolić K. Theoretical and experimental study of bilastine ionization. in 2nd International Conference on Chemo and Bioinformatics ICCBIKG 2023, BOOK OF PROCEEDINGS. 2023;:427-430.
doi:10.46793/ICCBI23.427PN .
Popović Nikolić, Marija, Popović, Gordana, Oljačić, Slavica, Nikolić, Katarina, "Theoretical and experimental study of bilastine ionization" in 2nd International Conference on Chemo and Bioinformatics ICCBIKG 2023, BOOK OF PROCEEDINGS (2023-09):427-430,
https://doi.org/10.46793/ICCBI23.427PN . .

3D-Quantitative Structure-Activity Relationship and design of novel Rho- associated protein kinases-1 (ROCK1) inhibitors

Beljkaš, Milan; Rebić, Jelena; Radan, Milica; Đikić, Teodora; Oljacic, Slavica; Nikolić, Katarina

(Institute for Information Technologies, University of Kragujevac, Serbia, 2023)

TY  - CONF
AU  - Beljkaš, Milan
AU  - Rebić, Jelena
AU  - Radan, Milica
AU  - Đikić, Teodora
AU  - Oljacic, Slavica
AU  - Nikolić, Katarina
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5043
AB  - Rho-associated coiled-coil kinases (ROCKs) are involved in essential
cellular functions such as adhesion, contraction, motility, proliferation, and cell
survival/apoptosis. Four ROCK inhibitors have already been approved by the FDA and
are used to treat glaucoma (ripasudil and netarsudil), cerebral vasospasm (fasudil), and
graft-versus-host disease (belumosudil). Recent studies have focused on exploring the
role of ROCK kinase inhibitors in cancer treatment and the development of new ROCK
inhibitors. The main objective of this study was to identify critical structural features
relevant to the inhibition of ROCK1 using a ligand-based 3D-QSAR (3D quantitative
structure-activity relationship) method. The 3D-QSAR model for ROCK1 was created
and validated using internal and external validation parameters (R2, Q2, R2pred, rm2, r/2m, 𝑟���������𝑚���������
2̅̅̅
and ∆r2m). The main structural features that correlate with the inhibition of ROCK1 were
identified (e.g., heterocycle with hydrogen donor group like nitrogen atom) and further
structural modifications of the ROCK1 inhibitors that contribute to increased activity
were proposed (removal of the amino group of the oxadiazole, modification of the
substituents of the phenyl ring).
PB  - Institute for Information Technologies, University of Kragujevac, Serbia
C3  - 2nd International Conference on Chemo and Bioinformatics, BOOK OF PROOCEEDINGS
T1  - 3D-Quantitative Structure-Activity Relationship and design of novel Rho- associated protein kinases-1 (ROCK1) inhibitors
SP  - 1584
EP  - 1588
DO  - 10.46793/ICCBI23.584B
ER  - 
@conference{
author = "Beljkaš, Milan and Rebić, Jelena and Radan, Milica and Đikić, Teodora and Oljacic, Slavica and Nikolić, Katarina",
year = "2023",
abstract = "Rho-associated coiled-coil kinases (ROCKs) are involved in essential
cellular functions such as adhesion, contraction, motility, proliferation, and cell
survival/apoptosis. Four ROCK inhibitors have already been approved by the FDA and
are used to treat glaucoma (ripasudil and netarsudil), cerebral vasospasm (fasudil), and
graft-versus-host disease (belumosudil). Recent studies have focused on exploring the
role of ROCK kinase inhibitors in cancer treatment and the development of new ROCK
inhibitors. The main objective of this study was to identify critical structural features
relevant to the inhibition of ROCK1 using a ligand-based 3D-QSAR (3D quantitative
structure-activity relationship) method. The 3D-QSAR model for ROCK1 was created
and validated using internal and external validation parameters (R2, Q2, R2pred, rm2, r/2m, 𝑟���������𝑚���������
2̅̅̅
and ∆r2m). The main structural features that correlate with the inhibition of ROCK1 were
identified (e.g., heterocycle with hydrogen donor group like nitrogen atom) and further
structural modifications of the ROCK1 inhibitors that contribute to increased activity
were proposed (removal of the amino group of the oxadiazole, modification of the
substituents of the phenyl ring).",
publisher = "Institute for Information Technologies, University of Kragujevac, Serbia",
journal = "2nd International Conference on Chemo and Bioinformatics, BOOK OF PROOCEEDINGS",
title = "3D-Quantitative Structure-Activity Relationship and design of novel Rho- associated protein kinases-1 (ROCK1) inhibitors",
pages = "1584-1588",
doi = "10.46793/ICCBI23.584B"
}
Beljkaš, M., Rebić, J., Radan, M., Đikić, T., Oljacic, S.,& Nikolić, K.. (2023). 3D-Quantitative Structure-Activity Relationship and design of novel Rho- associated protein kinases-1 (ROCK1) inhibitors. in 2nd International Conference on Chemo and Bioinformatics, BOOK OF PROOCEEDINGS
Institute for Information Technologies, University of Kragujevac, Serbia., 1584-1588.
https://doi.org/10.46793/ICCBI23.584B
Beljkaš M, Rebić J, Radan M, Đikić T, Oljacic S, Nikolić K. 3D-Quantitative Structure-Activity Relationship and design of novel Rho- associated protein kinases-1 (ROCK1) inhibitors. in 2nd International Conference on Chemo and Bioinformatics, BOOK OF PROOCEEDINGS. 2023;:1584-1588.
doi:10.46793/ICCBI23.584B .
Beljkaš, Milan, Rebić, Jelena, Radan, Milica, Đikić, Teodora, Oljacic, Slavica, Nikolić, Katarina, "3D-Quantitative Structure-Activity Relationship and design of novel Rho- associated protein kinases-1 (ROCK1) inhibitors" in 2nd International Conference on Chemo and Bioinformatics, BOOK OF PROOCEEDINGS (2023):1584-1588,
https://doi.org/10.46793/ICCBI23.584B . .

Virtual Docking, design and in silico ADMET profiling of novel Rho- associated protein kinases-1 (ROCK1) inhibitors

Beljkaš, Milan; Rebić, Jelena; Radan, Milica; Đikić, Teodora; Oljacic, Slavica; Nikolić, Katarina

(Institute for Information Technologies, University of Kragujevac, Serbia, 2023)

TY  - CONF
AU  - Beljkaš, Milan
AU  - Rebić, Jelena
AU  - Radan, Milica
AU  - Đikić, Teodora
AU  - Oljacic, Slavica
AU  - Nikolić, Katarina
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5041
AB  - Overexpression of Rho-associated protein kinases has been associated with various
diseases, including tumors. None of the approved ROCK inhibitors are used for cancer treatment.
However, some of them have been shown to have anti-tumor potential. The main objective of this
study was to develop novel ROCK1 inhibitors using the structure-based method, molecular
docking, and prediction of pharmacokinetic properties using the ADMET predictor. The key
interactions that strongly correlate with the activity of ROCK1 inhibitors are hydrogen bonds
between amino acid residues Met156, Glu154 and the hinge region of the inhibitors, indicating
possible structural changes in the hinge region of studied compounds. On the other hand, the
lack of interactions between 1,3-benzoxadiol moiety and the enzyme presents a promising
approach for further structural modifications in order to design more effective ROCK1 inhibitors.
All the important interactions between the developed ROCK1 inhibitors and the binding site
of the enzyme were established. They also showed acceptable pharmacokinetic properties and
could be further used for synthesis and evaluation by various biological assays.
PB  - Institute for Information Technologies, University of Kragujevac, Serbia
C3  - 2nd International Conference on Chemo and Bioinformatics ICCBIKG 2023, BOOK OF PROCEEDINGS
T1  - Virtual Docking, design and in silico ADMET profiling of novel Rho- associated protein kinases-1 (ROCK1) inhibitors
SP  - 1589
EP  - 1592
DO  - 10.46793/ICCBI23.589B
ER  - 
@conference{
author = "Beljkaš, Milan and Rebić, Jelena and Radan, Milica and Đikić, Teodora and Oljacic, Slavica and Nikolić, Katarina",
year = "2023",
abstract = "Overexpression of Rho-associated protein kinases has been associated with various
diseases, including tumors. None of the approved ROCK inhibitors are used for cancer treatment.
However, some of them have been shown to have anti-tumor potential. The main objective of this
study was to develop novel ROCK1 inhibitors using the structure-based method, molecular
docking, and prediction of pharmacokinetic properties using the ADMET predictor. The key
interactions that strongly correlate with the activity of ROCK1 inhibitors are hydrogen bonds
between amino acid residues Met156, Glu154 and the hinge region of the inhibitors, indicating
possible structural changes in the hinge region of studied compounds. On the other hand, the
lack of interactions between 1,3-benzoxadiol moiety and the enzyme presents a promising
approach for further structural modifications in order to design more effective ROCK1 inhibitors.
All the important interactions between the developed ROCK1 inhibitors and the binding site
of the enzyme were established. They also showed acceptable pharmacokinetic properties and
could be further used for synthesis and evaluation by various biological assays.",
publisher = "Institute for Information Technologies, University of Kragujevac, Serbia",
journal = "2nd International Conference on Chemo and Bioinformatics ICCBIKG 2023, BOOK OF PROCEEDINGS",
title = "Virtual Docking, design and in silico ADMET profiling of novel Rho- associated protein kinases-1 (ROCK1) inhibitors",
pages = "1589-1592",
doi = "10.46793/ICCBI23.589B"
}
Beljkaš, M., Rebić, J., Radan, M., Đikić, T., Oljacic, S.,& Nikolić, K.. (2023). Virtual Docking, design and in silico ADMET profiling of novel Rho- associated protein kinases-1 (ROCK1) inhibitors. in 2nd International Conference on Chemo and Bioinformatics ICCBIKG 2023, BOOK OF PROCEEDINGS
Institute for Information Technologies, University of Kragujevac, Serbia., 1589-1592.
https://doi.org/10.46793/ICCBI23.589B
Beljkaš M, Rebić J, Radan M, Đikić T, Oljacic S, Nikolić K. Virtual Docking, design and in silico ADMET profiling of novel Rho- associated protein kinases-1 (ROCK1) inhibitors. in 2nd International Conference on Chemo and Bioinformatics ICCBIKG 2023, BOOK OF PROCEEDINGS. 2023;:1589-1592.
doi:10.46793/ICCBI23.589B .
Beljkaš, Milan, Rebić, Jelena, Radan, Milica, Đikić, Teodora, Oljacic, Slavica, Nikolić, Katarina, "Virtual Docking, design and in silico ADMET profiling of novel Rho- associated protein kinases-1 (ROCK1) inhibitors" in 2nd International Conference on Chemo and Bioinformatics ICCBIKG 2023, BOOK OF PROCEEDINGS (2023):1589-1592,
https://doi.org/10.46793/ICCBI23.589B . .

The ionization of a cysteinyl leukotriene receptor antagonist, montelukast, in the presence of biomembrane mimetic systems

Popović-Nikolić, Marija; Oljačić, Slavica; Popović, Gordana; Nikolić, Katarina

(European Research Network on Signal Transduction CA18133, 2023)

TY  - CONF
AU  - Popović-Nikolić, Marija
AU  - Oljačić, Slavica
AU  - Popović, Gordana
AU  - Nikolić, Katarina
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5013
PB  - European Research Network on Signal Transduction CA18133
C3  - 3rd Transatlantic ECI GPCR Symposium - Early Career Investigators – September 7-8, 2023, Online event
T1  - The ionization of a cysteinyl leukotriene receptor antagonist, montelukast, in the presence of biomembrane mimetic systems
SP  - 35
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5013
ER  - 
@conference{
author = "Popović-Nikolić, Marija and Oljačić, Slavica and Popović, Gordana and Nikolić, Katarina",
year = "2023",
publisher = "European Research Network on Signal Transduction CA18133",
journal = "3rd Transatlantic ECI GPCR Symposium - Early Career Investigators – September 7-8, 2023, Online event",
title = "The ionization of a cysteinyl leukotriene receptor antagonist, montelukast, in the presence of biomembrane mimetic systems",
pages = "35",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5013"
}
Popović-Nikolić, M., Oljačić, S., Popović, G.,& Nikolić, K.. (2023). The ionization of a cysteinyl leukotriene receptor antagonist, montelukast, in the presence of biomembrane mimetic systems. in 3rd Transatlantic ECI GPCR Symposium - Early Career Investigators – September 7-8, 2023, Online event
European Research Network on Signal Transduction CA18133., 35.
https://hdl.handle.net/21.15107/rcub_farfar_5013
Popović-Nikolić M, Oljačić S, Popović G, Nikolić K. The ionization of a cysteinyl leukotriene receptor antagonist, montelukast, in the presence of biomembrane mimetic systems. in 3rd Transatlantic ECI GPCR Symposium - Early Career Investigators – September 7-8, 2023, Online event. 2023;:35.
https://hdl.handle.net/21.15107/rcub_farfar_5013 .
Popović-Nikolić, Marija, Oljačić, Slavica, Popović, Gordana, Nikolić, Katarina, "The ionization of a cysteinyl leukotriene receptor antagonist, montelukast, in the presence of biomembrane mimetic systems" in 3rd Transatlantic ECI GPCR Symposium - Early Career Investigators – September 7-8, 2023, Online event (2023):35,
https://hdl.handle.net/21.15107/rcub_farfar_5013 .

Virtual docking and design of novel Histone deacetylase and Rho- associated protein kinases dual inhibitors (HDAC/ROCKs)

Beljkaš, Milan; Petković, Miloš; Nikolić, Katarina; Oljačić, Slavica

(International Association of Physical Chemists, 2023)

TY  - CONF
AU  - Beljkaš, Milan
AU  - Petković, Miloš
AU  - Nikolić, Katarina
AU  - Oljačić, Slavica
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5005
AB  - Histone deacetylases (HDACs) belong to a family of epigenetic enzymes that has 18 different
isoforms and play an important role in the development and progression of various tumors.
To date, five histone deacetylase inhibitors have been approved by the FDA, and are used
to treat multiple myeloma, cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and
breast cancer (estrogen and/or progesterone positive) [1]. All of them are non-selective.
Therefore, their safety profile is poor and their efficacy is low in single therapy. One of our
previous research projects demonstrated the synergistic effect of HDAC inhibitors and
inhibitors of Rho-associated protein kinases (ROCK) in the treatment of pancreatic ductal
adenocarcinoma (PDAC) [2]. This finding led us to design of the dual HDAC/ROCK inhibitors
with potential effects on PDAC by using structure-based molecular docking method.
Molecular docking study was performed using GOLD software. The crystal structures of
ROCK1 (PDB: 6E9W), ROCK2 (PDB: 7JNT), HDAC1 (PDB: 5ICN), and HDAC6 (PDB: 5EDU)
enzymes were downloaded from the Protein Data Bank (PDB). The enzymes were prepared
for docking study using the online software Play Molecule-ProteinPrepare. The structures
of the ROCK1, ROCK2, HDAC1 and HDAC6 inhibitors with their pIC50 values were obtained
from the ChEMBL database. The dominant microspecies of all compounds at physiological
pH were selected by Marvin Sketch Sketch 6.1.0 program and their further geometrical
optimization were performed using the PM3 semi-empirical method and the Hartree-Fock
method with 3-21G basis set.
The virtual docking procedures for all four enzymes were validated and the calculated RMSD
values were below 2Å. The critical parts of the structures that establish the interactions
crucial for the inhibition of HDAC1, HDAC6, ROCK1, and ROCK2 were identified. Based on
the obtained resultsdual HDAC/ROCK inhibitors were designed and evaluated by validated
docking procedures and in silico ADMET profiling.
Taking into account all these findings, the most active compounds are selected and will be
further synthesized and evaluated using in vitro enzyme and cell tests.
PB  - International Association of Physical Chemists
C3  - 10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6
T1  - Virtual docking and design of novel Histone deacetylase and Rho- associated protein kinases dual inhibitors (HDAC/ROCKs)
SP  - 46
EP  - 46
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5005
ER  - 
@conference{
author = "Beljkaš, Milan and Petković, Miloš and Nikolić, Katarina and Oljačić, Slavica",
year = "2023",
abstract = "Histone deacetylases (HDACs) belong to a family of epigenetic enzymes that has 18 different
isoforms and play an important role in the development and progression of various tumors.
To date, five histone deacetylase inhibitors have been approved by the FDA, and are used
to treat multiple myeloma, cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and
breast cancer (estrogen and/or progesterone positive) [1]. All of them are non-selective.
Therefore, their safety profile is poor and their efficacy is low in single therapy. One of our
previous research projects demonstrated the synergistic effect of HDAC inhibitors and
inhibitors of Rho-associated protein kinases (ROCK) in the treatment of pancreatic ductal
adenocarcinoma (PDAC) [2]. This finding led us to design of the dual HDAC/ROCK inhibitors
with potential effects on PDAC by using structure-based molecular docking method.
Molecular docking study was performed using GOLD software. The crystal structures of
ROCK1 (PDB: 6E9W), ROCK2 (PDB: 7JNT), HDAC1 (PDB: 5ICN), and HDAC6 (PDB: 5EDU)
enzymes were downloaded from the Protein Data Bank (PDB). The enzymes were prepared
for docking study using the online software Play Molecule-ProteinPrepare. The structures
of the ROCK1, ROCK2, HDAC1 and HDAC6 inhibitors with their pIC50 values were obtained
from the ChEMBL database. The dominant microspecies of all compounds at physiological
pH were selected by Marvin Sketch Sketch 6.1.0 program and their further geometrical
optimization were performed using the PM3 semi-empirical method and the Hartree-Fock
method with 3-21G basis set.
The virtual docking procedures for all four enzymes were validated and the calculated RMSD
values were below 2Å. The critical parts of the structures that establish the interactions
crucial for the inhibition of HDAC1, HDAC6, ROCK1, and ROCK2 were identified. Based on
the obtained resultsdual HDAC/ROCK inhibitors were designed and evaluated by validated
docking procedures and in silico ADMET profiling.
Taking into account all these findings, the most active compounds are selected and will be
further synthesized and evaluated using in vitro enzyme and cell tests.",
publisher = "International Association of Physical Chemists",
journal = "10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6",
title = "Virtual docking and design of novel Histone deacetylase and Rho- associated protein kinases dual inhibitors (HDAC/ROCKs)",
pages = "46-46",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5005"
}
Beljkaš, M., Petković, M., Nikolić, K.,& Oljačić, S.. (2023). Virtual docking and design of novel Histone deacetylase and Rho- associated protein kinases dual inhibitors (HDAC/ROCKs). in 10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6
International Association of Physical Chemists., 46-46.
https://hdl.handle.net/21.15107/rcub_farfar_5005
Beljkaš M, Petković M, Nikolić K, Oljačić S. Virtual docking and design of novel Histone deacetylase and Rho- associated protein kinases dual inhibitors (HDAC/ROCKs). in 10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6. 2023;:46-46.
https://hdl.handle.net/21.15107/rcub_farfar_5005 .
Beljkaš, Milan, Petković, Miloš, Nikolić, Katarina, Oljačić, Slavica, "Virtual docking and design of novel Histone deacetylase and Rho- associated protein kinases dual inhibitors (HDAC/ROCKs)" in 10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6 (2023):46-46,
https://hdl.handle.net/21.15107/rcub_farfar_5005 .

Study of ionization of montelukast in differently charged micellar solutions as biomembrane mimetic systems

Popović-Nikolić, Marija; Oljačić, Slavica; Nikolić, Katarina; Popović, Gordana

(International Association of Physical Chemists, 2023)

TY  - CONF
AU  - Popović-Nikolić, Marija
AU  - Oljačić, Slavica
AU  - Nikolić, Katarina
AU  - Popović, Gordana
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5004
AB  - Montelukast is a leukotriene receptor antagonist indicated for asthma prophylaxis in adults
as well as in pediatric patients 6 months of age and older. Because it is associated with
numerous side effects, including neuropsychiatric events, it is very important to monitor its
pharmacologic behavior when administered chronically. To gain better insight into the
pharmacological properties of ionizable drugs, their physicochemical properties should be
studied under conditions more similar to physiological, such as micellar solutions of
surfactants as biomembrane mimetic systems. Montelukast is an ampholyte with one acidic
(carboxyl) and one basic (quinoline nitrogen) group. In this study the effects of micellar
solutions of differently charged surfactants (anionic SDS, cationic CTAB, and nonionic TX-
100) on protolytic equilibria of montelukast were investigated potentiometrically. Solutions were titrated with standard NaOH solution (0.1017 M) at a constant ionic strength (0.1 M NaCl) and a temperature 25°C. Experimental data were analyzed using the Hyperquad program. Due to poor water solubility, the pKa values defining the ionization in water (pKa1 =4.07, pKa2 = 5.49), were obtained indirectly by extrapolation from the pKa* values determined potentiometrically in the different methanol-water mixtures (40%, 50%, and 55% wt/wt). The pKa values in 0.01M micellar solutions were determined without the use of cosolvent. Micelles contributed to the shift in protolytic equilibria of montelukast, anionic ΔpKa up to +1.20, cationic ΔpKa up to +0.27, and nonionic ΔpKa up to +0.98. More pronounced effects are observed on the ionization of carboxyl group than quinoline nitrogen. A change in the distribution of equilibrium forms in a relation to pure water, can be expected in physiological conditions, in interactions of montelukast with polar or charged biomolecules.
PB  - International Association of Physical Chemists
C3  - 10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6
T1  - Study of ionization of montelukast in differently charged micellar solutions as biomembrane mimetic systems
SP  - 49
EP  - 49
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5004
ER  - 
@conference{
author = "Popović-Nikolić, Marija and Oljačić, Slavica and Nikolić, Katarina and Popović, Gordana",
year = "2023",
abstract = "Montelukast is a leukotriene receptor antagonist indicated for asthma prophylaxis in adults
as well as in pediatric patients 6 months of age and older. Because it is associated with
numerous side effects, including neuropsychiatric events, it is very important to monitor its
pharmacologic behavior when administered chronically. To gain better insight into the
pharmacological properties of ionizable drugs, their physicochemical properties should be
studied under conditions more similar to physiological, such as micellar solutions of
surfactants as biomembrane mimetic systems. Montelukast is an ampholyte with one acidic
(carboxyl) and one basic (quinoline nitrogen) group. In this study the effects of micellar
solutions of differently charged surfactants (anionic SDS, cationic CTAB, and nonionic TX-
100) on protolytic equilibria of montelukast were investigated potentiometrically. Solutions were titrated with standard NaOH solution (0.1017 M) at a constant ionic strength (0.1 M NaCl) and a temperature 25°C. Experimental data were analyzed using the Hyperquad program. Due to poor water solubility, the pKa values defining the ionization in water (pKa1 =4.07, pKa2 = 5.49), were obtained indirectly by extrapolation from the pKa* values determined potentiometrically in the different methanol-water mixtures (40%, 50%, and 55% wt/wt). The pKa values in 0.01M micellar solutions were determined without the use of cosolvent. Micelles contributed to the shift in protolytic equilibria of montelukast, anionic ΔpKa up to +1.20, cationic ΔpKa up to +0.27, and nonionic ΔpKa up to +0.98. More pronounced effects are observed on the ionization of carboxyl group than quinoline nitrogen. A change in the distribution of equilibrium forms in a relation to pure water, can be expected in physiological conditions, in interactions of montelukast with polar or charged biomolecules.",
publisher = "International Association of Physical Chemists",
journal = "10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6",
title = "Study of ionization of montelukast in differently charged micellar solutions as biomembrane mimetic systems",
pages = "49-49",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5004"
}
Popović-Nikolić, M., Oljačić, S., Nikolić, K.,& Popović, G.. (2023). Study of ionization of montelukast in differently charged micellar solutions as biomembrane mimetic systems. in 10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6
International Association of Physical Chemists., 49-49.
https://hdl.handle.net/21.15107/rcub_farfar_5004
Popović-Nikolić M, Oljačić S, Nikolić K, Popović G. Study of ionization of montelukast in differently charged micellar solutions as biomembrane mimetic systems. in 10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6. 2023;:49-49.
https://hdl.handle.net/21.15107/rcub_farfar_5004 .
Popović-Nikolić, Marija, Oljačić, Slavica, Nikolić, Katarina, Popović, Gordana, "Study of ionization of montelukast in differently charged micellar solutions as biomembrane mimetic systems" in 10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6 (2023):49-49,
https://hdl.handle.net/21.15107/rcub_farfar_5004 .

DFT approach of the redox properties of brimonidine and varenicline

Popović Nikolić, Marija; Nikolić, Katarina; Aleksić, Mara

(Institute for Information Technologies, University of Kragujevac, Serbia, 2023)

TY  - CONF
AU  - Popović Nikolić, Marija
AU  - Nikolić, Katarina
AU  - Aleksić, Mara
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5044
AB  - he redox properties of two quinoxaline derivatives, brimonidine and varenicline,
previously studied electrochemically, were evaluated by performing a computational study. On
the basis of some useful quantum chemical parameters the differences and similarities between
their redox features were explained. The obtained results support the experimental findings that
the redox processes of both compounds are under strong influence of the solution pH, whereas
the reduction of brimonidine occurs easier than the reduction of varenicline, at corresponding pH
values.
PB  - Institute for Information Technologies, University of Kragujevac, Serbia
C3  - 2nd International Conference on Chemo and Bioinformatics ICCBIKG 2023, BOOK OF PROCEEDINGS
T1  - DFT approach of the redox properties of brimonidine and varenicline
SP  - 423
EP  - 426
DO  - 10.46793/ICCBI23.423PN
ER  - 
@conference{
author = "Popović Nikolić, Marija and Nikolić, Katarina and Aleksić, Mara",
year = "2023",
abstract = "he redox properties of two quinoxaline derivatives, brimonidine and varenicline,
previously studied electrochemically, were evaluated by performing a computational study. On
the basis of some useful quantum chemical parameters the differences and similarities between
their redox features were explained. The obtained results support the experimental findings that
the redox processes of both compounds are under strong influence of the solution pH, whereas
the reduction of brimonidine occurs easier than the reduction of varenicline, at corresponding pH
values.",
publisher = "Institute for Information Technologies, University of Kragujevac, Serbia",
journal = "2nd International Conference on Chemo and Bioinformatics ICCBIKG 2023, BOOK OF PROCEEDINGS",
title = "DFT approach of the redox properties of brimonidine and varenicline",
pages = "423-426",
doi = "10.46793/ICCBI23.423PN"
}
Popović Nikolić, M., Nikolić, K.,& Aleksić, M.. (2023). DFT approach of the redox properties of brimonidine and varenicline. in 2nd International Conference on Chemo and Bioinformatics ICCBIKG 2023, BOOK OF PROCEEDINGS
Institute for Information Technologies, University of Kragujevac, Serbia., 423-426.
https://doi.org/10.46793/ICCBI23.423PN
Popović Nikolić M, Nikolić K, Aleksić M. DFT approach of the redox properties of brimonidine and varenicline. in 2nd International Conference on Chemo and Bioinformatics ICCBIKG 2023, BOOK OF PROCEEDINGS. 2023;:423-426.
doi:10.46793/ICCBI23.423PN .
Popović Nikolić, Marija, Nikolić, Katarina, Aleksić, Mara, "DFT approach of the redox properties of brimonidine and varenicline" in 2nd International Conference on Chemo and Bioinformatics ICCBIKG 2023, BOOK OF PROCEEDINGS (2023):423-426,
https://doi.org/10.46793/ICCBI23.423PN . .

Protolytic equilibria of ACE inhibitors in micellar solution of nonionic surfactant Brij 35

Popović-Nikolić, Marija; Nikolić, Katarina; Popović, Gordana

(Springer, 2023)

TY  - JOUR
AU  - Popović-Nikolić, Marija
AU  - Nikolić, Katarina
AU  - Popović, Gordana
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4687
AB  - The acid–base equilibria of six ACE inhibitors (ACEIs), captopril, cilazapril, enalapril, lisinopril, quinapril, and rami-
pril, were investigated in the presence of micelles of nonionic surfactant Brij 35. The pKa values were potentiometrically
determined at 25 °C and at a constant ionic strength (0.1 M NaCl). The obtained potentiometric data were evaluated in the
computer program Hyperquad. On the basis of the shift in the pKa values (ΔpKa ) determined in micellar media in relation
to the pKa values previously determined in “pure” water, the effect of Brij 35 micelles on ACEIs ionization was estimated.
The presence of nonionic Brij 35 micelles caused a shift in the pKa values of all ionizable groups of the investigated ACEIs
(ΔpKa from − 3.44 to + 1.9) while shifting the protolytic equilibria of both acidic and basic groups toward the molecular
form. The Brij 35 micelles expressed the most pronounced effect on the ionization of captopril among the investigated ACEIs
and stronger effect on the ionization of amino than on the ionization of carboxyl groups. The obtained results suggest that
ionizable functional groups of ACEIs are involved in interactions with palisade layer of nonionic Brij 35 micelles, which
potentially can be considered in physiological conditions. Distribution diagrams of the investigated ACEIs equilibrium
forms as a function of pH indicate that the change in distribution is most strongly expressed in pH range 4–8, which includes
biopharmaceutically important pH values.
PB  - Springer
T2  - Monatshefte für Chemie - Chemical Monthly
T1  - Protolytic equilibria of ACE inhibitors in micellar solution of nonionic surfactant Brij 35
VL  - 154
SP  - 615
EP  - 624
DO  - 10.1007/s00706-023-03059-2
ER  - 
@article{
author = "Popović-Nikolić, Marija and Nikolić, Katarina and Popović, Gordana",
year = "2023",
abstract = "The acid–base equilibria of six ACE inhibitors (ACEIs), captopril, cilazapril, enalapril, lisinopril, quinapril, and rami-
pril, were investigated in the presence of micelles of nonionic surfactant Brij 35. The pKa values were potentiometrically
determined at 25 °C and at a constant ionic strength (0.1 M NaCl). The obtained potentiometric data were evaluated in the
computer program Hyperquad. On the basis of the shift in the pKa values (ΔpKa ) determined in micellar media in relation
to the pKa values previously determined in “pure” water, the effect of Brij 35 micelles on ACEIs ionization was estimated.
The presence of nonionic Brij 35 micelles caused a shift in the pKa values of all ionizable groups of the investigated ACEIs
(ΔpKa from − 3.44 to + 1.9) while shifting the protolytic equilibria of both acidic and basic groups toward the molecular
form. The Brij 35 micelles expressed the most pronounced effect on the ionization of captopril among the investigated ACEIs
and stronger effect on the ionization of amino than on the ionization of carboxyl groups. The obtained results suggest that
ionizable functional groups of ACEIs are involved in interactions with palisade layer of nonionic Brij 35 micelles, which
potentially can be considered in physiological conditions. Distribution diagrams of the investigated ACEIs equilibrium
forms as a function of pH indicate that the change in distribution is most strongly expressed in pH range 4–8, which includes
biopharmaceutically important pH values.",
publisher = "Springer",
journal = "Monatshefte für Chemie - Chemical Monthly",
title = "Protolytic equilibria of ACE inhibitors in micellar solution of nonionic surfactant Brij 35",
volume = "154",
pages = "615-624",
doi = "10.1007/s00706-023-03059-2"
}
Popović-Nikolić, M., Nikolić, K.,& Popović, G.. (2023). Protolytic equilibria of ACE inhibitors in micellar solution of nonionic surfactant Brij 35. in Monatshefte für Chemie - Chemical Monthly
Springer., 154, 615-624.
https://doi.org/10.1007/s00706-023-03059-2
Popović-Nikolić M, Nikolić K, Popović G. Protolytic equilibria of ACE inhibitors in micellar solution of nonionic surfactant Brij 35. in Monatshefte für Chemie - Chemical Monthly. 2023;154:615-624.
doi:10.1007/s00706-023-03059-2 .
Popović-Nikolić, Marija, Nikolić, Katarina, Popović, Gordana, "Protolytic equilibria of ACE inhibitors in micellar solution of nonionic surfactant Brij 35" in Monatshefte für Chemie - Chemical Monthly, 154 (2023):615-624,
https://doi.org/10.1007/s00706-023-03059-2 . .

Towards the multitarget HDAC Inhibitors for the treatment of pancreatic carcinoma by joining the drug synergy predictions and the molecular modeling

Đoković, Nemanja; Ilić, Aleksandra; Čebzan, Alen; Radović, Branko; Ružić, Dušan; Đurić, Ana; Srdić-Rajić, Tatjana; Nikolić, Katarina

(International Association of Physical Chemists, 2023)

TY  - CONF
AU  - Đoković, Nemanja
AU  - Ilić, Aleksandra
AU  - Čebzan, Alen
AU  - Radović, Branko
AU  - Ružić, Dušan
AU  - Đurić, Ana
AU  - Srdić-Rajić, Tatjana
AU  - Nikolić, Katarina
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5001
AB  - Pancreatic ductal adenocarcinoma (PDAC) ranks among the most formidable and deadly
types of cancer. The emergence of chemoresistance in PDAC plays a significant role in the
unfavorable survival rates, making it imperative to swiftly develop new pharmaceutical
strategies to address this issue and improve treatment outcomes for PDAC (1). Considering
the numerous epigenetic changes observed in PDAC, the utilization of epigenetic drugs,
such as histone deacetylase (HDAC) inhibitors, holds a great promise as a transformative
approach, particularly when used in combination therapy settings (2).
In this study, we investigated the potential of utilizing drug sensitivity data and the basal
gene expression of pancreatic carcinoma cell lines to develop a bioinformatics screening
protocol for prediction of the combinatorial options available for HDAC inhibitors, including
sirtuin (SIRT) inhibitors. Experimental validation of the protocol performed on the two
pancreatic carcinoma cell lines (MIA PaCa-2 cells and PANC-1) confirmed the identified
synergisms between HDAC inhibitors and sphingosine 1-phosphate (S1P) receptor agonist
– fingolimod, or HDAC inhibitors and Rho-associated protein kinase (ROCK) inhibitor – RKI1447 (3).
Developed bioinformatics screening protocol for predictions of synergistic drug
combinations in PDAC identified several previously unreported interaction partners of
HDAC inhibitors. Predicted interaction partners of HDAC inhibitors including Aurora Kinase
A (AURKA) inhibitor, glutaminase (GLS) inhibitor and WEE1 kinase inhibitor were selected
for the design of novel classes of dual-acting HDAC inhibitors by the means of structure-based molecular modelling. Novel dual inhibitors (SIRT/AURKA, HDAC/GLS and HDAC/WEE1)
were designed relying on the known pharmacophoric features and molecular docking
models developed for each of the targets of interest. The docking scores of the designed
inhibitors revealed a notable affinity towards the specific targets. Additionally, when
combined with predictions of drug synergy, these designed molecules exhibit great
potential as promising structures for subsequent experimental evaluation.
PB  - International Association of Physical Chemists
C3  - 10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6
T1  - Towards the multitarget HDAC Inhibitors for the treatment of pancreatic carcinoma by joining the drug synergy predictions and the molecular modeling
SP  - 47
EP  - 47
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5001
ER  - 
@conference{
author = "Đoković, Nemanja and Ilić, Aleksandra and Čebzan, Alen and Radović, Branko and Ružić, Dušan and Đurić, Ana and Srdić-Rajić, Tatjana and Nikolić, Katarina",
year = "2023",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) ranks among the most formidable and deadly
types of cancer. The emergence of chemoresistance in PDAC plays a significant role in the
unfavorable survival rates, making it imperative to swiftly develop new pharmaceutical
strategies to address this issue and improve treatment outcomes for PDAC (1). Considering
the numerous epigenetic changes observed in PDAC, the utilization of epigenetic drugs,
such as histone deacetylase (HDAC) inhibitors, holds a great promise as a transformative
approach, particularly when used in combination therapy settings (2).
In this study, we investigated the potential of utilizing drug sensitivity data and the basal
gene expression of pancreatic carcinoma cell lines to develop a bioinformatics screening
protocol for prediction of the combinatorial options available for HDAC inhibitors, including
sirtuin (SIRT) inhibitors. Experimental validation of the protocol performed on the two
pancreatic carcinoma cell lines (MIA PaCa-2 cells and PANC-1) confirmed the identified
synergisms between HDAC inhibitors and sphingosine 1-phosphate (S1P) receptor agonist
– fingolimod, or HDAC inhibitors and Rho-associated protein kinase (ROCK) inhibitor – RKI1447 (3).
Developed bioinformatics screening protocol for predictions of synergistic drug
combinations in PDAC identified several previously unreported interaction partners of
HDAC inhibitors. Predicted interaction partners of HDAC inhibitors including Aurora Kinase
A (AURKA) inhibitor, glutaminase (GLS) inhibitor and WEE1 kinase inhibitor were selected
for the design of novel classes of dual-acting HDAC inhibitors by the means of structure-based molecular modelling. Novel dual inhibitors (SIRT/AURKA, HDAC/GLS and HDAC/WEE1)
were designed relying on the known pharmacophoric features and molecular docking
models developed for each of the targets of interest. The docking scores of the designed
inhibitors revealed a notable affinity towards the specific targets. Additionally, when
combined with predictions of drug synergy, these designed molecules exhibit great
potential as promising structures for subsequent experimental evaluation.",
publisher = "International Association of Physical Chemists",
journal = "10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6",
title = "Towards the multitarget HDAC Inhibitors for the treatment of pancreatic carcinoma by joining the drug synergy predictions and the molecular modeling",
pages = "47-47",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5001"
}
Đoković, N., Ilić, A., Čebzan, A., Radović, B., Ružić, D., Đurić, A., Srdić-Rajić, T.,& Nikolić, K.. (2023). Towards the multitarget HDAC Inhibitors for the treatment of pancreatic carcinoma by joining the drug synergy predictions and the molecular modeling. in 10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6
International Association of Physical Chemists., 47-47.
https://hdl.handle.net/21.15107/rcub_farfar_5001
Đoković N, Ilić A, Čebzan A, Radović B, Ružić D, Đurić A, Srdić-Rajić T, Nikolić K. Towards the multitarget HDAC Inhibitors for the treatment of pancreatic carcinoma by joining the drug synergy predictions and the molecular modeling. in 10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6. 2023;:47-47.
https://hdl.handle.net/21.15107/rcub_farfar_5001 .
Đoković, Nemanja, Ilić, Aleksandra, Čebzan, Alen, Radović, Branko, Ružić, Dušan, Đurić, Ana, Srdić-Rajić, Tatjana, Nikolić, Katarina, "Towards the multitarget HDAC Inhibitors for the treatment of pancreatic carcinoma by joining the drug synergy predictions and the molecular modeling" in 10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6 (2023):47-47,
https://hdl.handle.net/21.15107/rcub_farfar_5001 .

Computer-aided drug design of MAPK inhibitors by combined 3D-QSAR analysis and molecular docking

Čebzan, Alen; Ružić, Dušan; Nikolić, Katarina

(European Association for Cancer Research, 2023)

TY  - CONF
AU  - Čebzan, Alen
AU  - Ružić, Dušan
AU  - Nikolić, Katarina
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4952
PB  - European Association for Cancer Research
C3  - EACR-Boehringer Ingelheim Drugging and Regulating the MAP Kinase Pathway Virtual Event, Worldwide : 21 - 22 February 2023
T1  - Computer-aided drug design of MAPK inhibitors by combined 3D-QSAR analysis and molecular docking
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4952
ER  - 
@conference{
author = "Čebzan, Alen and Ružić, Dušan and Nikolić, Katarina",
year = "2023",
publisher = "European Association for Cancer Research",
journal = "EACR-Boehringer Ingelheim Drugging and Regulating the MAP Kinase Pathway Virtual Event, Worldwide : 21 - 22 February 2023",
title = "Computer-aided drug design of MAPK inhibitors by combined 3D-QSAR analysis and molecular docking",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4952"
}
Čebzan, A., Ružić, D.,& Nikolić, K.. (2023). Computer-aided drug design of MAPK inhibitors by combined 3D-QSAR analysis and molecular docking. in EACR-Boehringer Ingelheim Drugging and Regulating the MAP Kinase Pathway Virtual Event, Worldwide : 21 - 22 February 2023
European Association for Cancer Research..
https://hdl.handle.net/21.15107/rcub_farfar_4952
Čebzan A, Ružić D, Nikolić K. Computer-aided drug design of MAPK inhibitors by combined 3D-QSAR analysis and molecular docking. in EACR-Boehringer Ingelheim Drugging and Regulating the MAP Kinase Pathway Virtual Event, Worldwide : 21 - 22 February 2023. 2023;.
https://hdl.handle.net/21.15107/rcub_farfar_4952 .
Čebzan, Alen, Ružić, Dušan, Nikolić, Katarina, "Computer-aided drug design of MAPK inhibitors by combined 3D-QSAR analysis and molecular docking" in EACR-Boehringer Ingelheim Drugging and Regulating the MAP Kinase Pathway Virtual Event, Worldwide : 21 - 22 February 2023 (2023),
https://hdl.handle.net/21.15107/rcub_farfar_4952 .

Reversible Control of RNA Splicing by Photoswitchable Small Molecules

Zhang, Lei; Xie, Xiulan; Đoković, Nemanja; Nikolić, Katarina; Kosenkov, Dmitri; Abendroth, Frank; Vázquez, Olalla

(American Chemical Society, 2023)

TY  - JOUR
AU  - Zhang, Lei
AU  - Xie, Xiulan
AU  - Đoković, Nemanja
AU  - Nikolić, Katarina
AU  - Kosenkov, Dmitri
AU  - Abendroth, Frank
AU  - Vázquez, Olalla
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4913
AB  - Dynamics are intrinsic to both RNA function and
structure. Yet, the available means to precisely provide RNA-based
processes with spatiotemporal resolution are scarce. Here, our
work pioneers a reversible approach to regulate RNA splicing
within primary patient-derived cells by synthetic photoswitches.
Our small molecule enables conditional real-time control at mRNA
and protein levels. NMR experiments, together with theoretical
calculations, photochemical characterization, fluorescence polarization
measurements, and living cell-based assays, confirmed lightdependent
exon inclusion as well as an increase in the target
functional protein. Therefore, we first demonstrated the potential
of photopharmacology modulation in splicing, tweaking the
current optochemical toolkit. The timeliness on the consolidation
of RNA research as the driving force toward therapeutical innovation holds the promise that our approach will contribute to
redrawing the vision of RNA.
PB  - American Chemical Society
T2  - Journal of the American Chemical Society
T1  - Reversible Control of RNA Splicing by Photoswitchable Small Molecules
VL  - 145
IS  - 23
SP  - 12783
EP  - 12792
DO  - 10.1021/jacs.3c03275
ER  - 
@article{
author = "Zhang, Lei and Xie, Xiulan and Đoković, Nemanja and Nikolić, Katarina and Kosenkov, Dmitri and Abendroth, Frank and Vázquez, Olalla",
year = "2023",
abstract = "Dynamics are intrinsic to both RNA function and
structure. Yet, the available means to precisely provide RNA-based
processes with spatiotemporal resolution are scarce. Here, our
work pioneers a reversible approach to regulate RNA splicing
within primary patient-derived cells by synthetic photoswitches.
Our small molecule enables conditional real-time control at mRNA
and protein levels. NMR experiments, together with theoretical
calculations, photochemical characterization, fluorescence polarization
measurements, and living cell-based assays, confirmed lightdependent
exon inclusion as well as an increase in the target
functional protein. Therefore, we first demonstrated the potential
of photopharmacology modulation in splicing, tweaking the
current optochemical toolkit. The timeliness on the consolidation
of RNA research as the driving force toward therapeutical innovation holds the promise that our approach will contribute to
redrawing the vision of RNA.",
publisher = "American Chemical Society",
journal = "Journal of the American Chemical Society",
title = "Reversible Control of RNA Splicing by Photoswitchable Small Molecules",
volume = "145",
number = "23",
pages = "12783-12792",
doi = "10.1021/jacs.3c03275"
}
Zhang, L., Xie, X., Đoković, N., Nikolić, K., Kosenkov, D., Abendroth, F.,& Vázquez, O.. (2023). Reversible Control of RNA Splicing by Photoswitchable Small Molecules. in Journal of the American Chemical Society
American Chemical Society., 145(23), 12783-12792.
https://doi.org/10.1021/jacs.3c03275
Zhang L, Xie X, Đoković N, Nikolić K, Kosenkov D, Abendroth F, Vázquez O. Reversible Control of RNA Splicing by Photoswitchable Small Molecules. in Journal of the American Chemical Society. 2023;145(23):12783-12792.
doi:10.1021/jacs.3c03275 .
Zhang, Lei, Xie, Xiulan, Đoković, Nemanja, Nikolić, Katarina, Kosenkov, Dmitri, Abendroth, Frank, Vázquez, Olalla, "Reversible Control of RNA Splicing by Photoswitchable Small Molecules" in Journal of the American Chemical Society, 145, no. 23 (2023):12783-12792,
https://doi.org/10.1021/jacs.3c03275 . .
32
2
1

Correlating Basal Gene Expression across Chemical Sensitivity Data to Screen for Novel Synergistic Interactors of HDAC Inhibitors in Pancreatic Carcinoma

Đoković, Nemanja; Đurić, Ana; Ružić, Dušan; Srdić-Rajić, Tatjana; Nikolić, Katarina

(MDPI, 2023)

TY  - JOUR
AU  - Đoković, Nemanja
AU  - Đurić, Ana
AU  - Ružić, Dušan
AU  - Srdić-Rajić, Tatjana
AU  - Nikolić, Katarina
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4472
AB  - Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal malignancies. Development of the chemoresistance in the PDAC is one of the key contributors to the poor survival outcomes and the major reason for urgent development of novel pharmacological approaches in a treatment of PDAC. Systematically tailored combination therapy holds the promise for advancing the treatment of PDAC. However, the number of possible combinations of pharmacological agents is too large to be explored experimentally. In respect to the many epigenetic alterations in PDAC, epigenetic drugs including histone deacetylase inhibitors (HDACi) could be seen as the game changers especially in combined therapy settings. In this work, we explored a possibility of using drug-sensitivity data together with the basal gene expression of pancreatic cell lines to predict combinatorial options available for HDACi. Developed bioinformatics screening protocol for predictions of synergistic drug combinations in PDAC identified the sphingolipid signaling pathway with associated downstream effectors as a promising novel targets for future development of multi-target therapeutics or combined therapy with HDACi. Through the experimental validation, we have characterized novel synergism between HDACi and a Rho-associated protein kinase (ROCK) inhibitor RKI-1447, and between HDACi and a sphingosine 1-phosphate (S1P) receptor agonist fingolimod.
PB  - MDPI
T2  - Pharmaceuticals
T1  - Correlating Basal Gene Expression across Chemical Sensitivity Data to Screen for Novel Synergistic Interactors of HDAC Inhibitors in Pancreatic Carcinoma
VL  - 16
IS  - 2
DO  - 10.3390/ph16020294
ER  - 
@article{
author = "Đoković, Nemanja and Đurić, Ana and Ružić, Dušan and Srdić-Rajić, Tatjana and Nikolić, Katarina",
year = "2023",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal malignancies. Development of the chemoresistance in the PDAC is one of the key contributors to the poor survival outcomes and the major reason for urgent development of novel pharmacological approaches in a treatment of PDAC. Systematically tailored combination therapy holds the promise for advancing the treatment of PDAC. However, the number of possible combinations of pharmacological agents is too large to be explored experimentally. In respect to the many epigenetic alterations in PDAC, epigenetic drugs including histone deacetylase inhibitors (HDACi) could be seen as the game changers especially in combined therapy settings. In this work, we explored a possibility of using drug-sensitivity data together with the basal gene expression of pancreatic cell lines to predict combinatorial options available for HDACi. Developed bioinformatics screening protocol for predictions of synergistic drug combinations in PDAC identified the sphingolipid signaling pathway with associated downstream effectors as a promising novel targets for future development of multi-target therapeutics or combined therapy with HDACi. Through the experimental validation, we have characterized novel synergism between HDACi and a Rho-associated protein kinase (ROCK) inhibitor RKI-1447, and between HDACi and a sphingosine 1-phosphate (S1P) receptor agonist fingolimod.",
publisher = "MDPI",
journal = "Pharmaceuticals",
title = "Correlating Basal Gene Expression across Chemical Sensitivity Data to Screen for Novel Synergistic Interactors of HDAC Inhibitors in Pancreatic Carcinoma",
volume = "16",
number = "2",
doi = "10.3390/ph16020294"
}
Đoković, N., Đurić, A., Ružić, D., Srdić-Rajić, T.,& Nikolić, K.. (2023). Correlating Basal Gene Expression across Chemical Sensitivity Data to Screen for Novel Synergistic Interactors of HDAC Inhibitors in Pancreatic Carcinoma. in Pharmaceuticals
MDPI., 16(2).
https://doi.org/10.3390/ph16020294
Đoković N, Đurić A, Ružić D, Srdić-Rajić T, Nikolić K. Correlating Basal Gene Expression across Chemical Sensitivity Data to Screen for Novel Synergistic Interactors of HDAC Inhibitors in Pancreatic Carcinoma. in Pharmaceuticals. 2023;16(2).
doi:10.3390/ph16020294 .
Đoković, Nemanja, Đurić, Ana, Ružić, Dušan, Srdić-Rajić, Tatjana, Nikolić, Katarina, "Correlating Basal Gene Expression across Chemical Sensitivity Data to Screen for Novel Synergistic Interactors of HDAC Inhibitors in Pancreatic Carcinoma" in Pharmaceuticals, 16, no. 2 (2023),
https://doi.org/10.3390/ph16020294 . .

Electrochemical and theoretical study on interaction between erlotinib and DNA

Jovanović, Milan; Nikolić, Katarina; Čarapić, Marija; Aleksić, Mara

(Elsevier B.V., 2023)

TY  - JOUR
AU  - Jovanović, Milan
AU  - Nikolić, Katarina
AU  - Čarapić, Marija
AU  - Aleksić, Mara
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4931
AB  - A comprehensive investigation of tyrosine kinase inhibitor erlotinib (ERL) electrochemical behavior and interaction with DNA was performed with the aim to clarify its redox mechanism and to determine the mode of binding. Irreversible oxidation and reduction processes of ERL on glassy carbon electrode were investigated using three voltammetric techniques CV, DPV, SWV in pH range between 2.0 and 9.0. Oxidation was established as an adsorption-controlled process, while the reduction manifested diffusion-adsorption mixed controlled process in acidic medium and adsorption became predominant in the neutral solutions. According to the determined number of transferred electrons and protons, oxidation and reduction mechanism of ERL are proposed. To follow the interaction between ERL and DNA, the multilayer ct-DNA electrochemical biosensor was incubated in ERL solutions concentrations ranged from 2 × 10–7 M to 5 × 10–5 M (pH 4.6) for 30 min. SWV measurements have shown the decrease in deoxyadenosine peak current as a consequence of ERL increased concentration and binding to ct-DNA. The calculated value of binding constant was K = 8.25 × 104 M−1. Molecular docking showed that ERL forms hydrophobic interactions when docked into minor groove, as well as when intercalated, and molecular dynamics analysis predicted the stability of obtained complexes. These results together with voltammetric studies imply that the intercalation could be more dominant way ERL binding to DNA compared to minor groove binding.
PB  - Elsevier B.V.
T2  - Journal of Pharmaceutical and Biomedical Analysis
T1  - Electrochemical and theoretical study on interaction between erlotinib and DNA
VL  - 234
DO  - 10.1016/j.jpba.2023.115560
ER  - 
@article{
author = "Jovanović, Milan and Nikolić, Katarina and Čarapić, Marija and Aleksić, Mara",
year = "2023",
abstract = "A comprehensive investigation of tyrosine kinase inhibitor erlotinib (ERL) electrochemical behavior and interaction with DNA was performed with the aim to clarify its redox mechanism and to determine the mode of binding. Irreversible oxidation and reduction processes of ERL on glassy carbon electrode were investigated using three voltammetric techniques CV, DPV, SWV in pH range between 2.0 and 9.0. Oxidation was established as an adsorption-controlled process, while the reduction manifested diffusion-adsorption mixed controlled process in acidic medium and adsorption became predominant in the neutral solutions. According to the determined number of transferred electrons and protons, oxidation and reduction mechanism of ERL are proposed. To follow the interaction between ERL and DNA, the multilayer ct-DNA electrochemical biosensor was incubated in ERL solutions concentrations ranged from 2 × 10–7 M to 5 × 10–5 M (pH 4.6) for 30 min. SWV measurements have shown the decrease in deoxyadenosine peak current as a consequence of ERL increased concentration and binding to ct-DNA. The calculated value of binding constant was K = 8.25 × 104 M−1. Molecular docking showed that ERL forms hydrophobic interactions when docked into minor groove, as well as when intercalated, and molecular dynamics analysis predicted the stability of obtained complexes. These results together with voltammetric studies imply that the intercalation could be more dominant way ERL binding to DNA compared to minor groove binding.",
publisher = "Elsevier B.V.",
journal = "Journal of Pharmaceutical and Biomedical Analysis",
title = "Electrochemical and theoretical study on interaction between erlotinib and DNA",
volume = "234",
doi = "10.1016/j.jpba.2023.115560"
}
Jovanović, M., Nikolić, K., Čarapić, M.,& Aleksić, M.. (2023). Electrochemical and theoretical study on interaction between erlotinib and DNA. in Journal of Pharmaceutical and Biomedical Analysis
Elsevier B.V.., 234.
https://doi.org/10.1016/j.jpba.2023.115560
Jovanović M, Nikolić K, Čarapić M, Aleksić M. Electrochemical and theoretical study on interaction between erlotinib and DNA. in Journal of Pharmaceutical and Biomedical Analysis. 2023;234.
doi:10.1016/j.jpba.2023.115560 .
Jovanović, Milan, Nikolić, Katarina, Čarapić, Marija, Aleksić, Mara, "Electrochemical and theoretical study on interaction between erlotinib and DNA" in Journal of Pharmaceutical and Biomedical Analysis, 234 (2023),
https://doi.org/10.1016/j.jpba.2023.115560 . .
1

Polypharmacological strategy in rational drug design of new dual 5HT2A/D2-R antagonists as potentially effective therapeutics of complex neurological and mental disorders

Nikolić, Katarina; Radan, Milica; Đikić, Teodora

(European Research Network on Signal Transduction CA18133 (ERNEST), 2023)

TY  - CONF
AU  - Nikolić, Katarina
AU  - Radan, Milica
AU  - Đikić, Teodora
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4762
PB  - European Research Network on Signal Transduction CA18133 (ERNEST)
C3  - 8th and final ERNEST Meeting "GPCR structure and function: The present and perspectives for the future”, May 3-7, 2023 in Crete, Greece
T1  - Polypharmacological strategy in rational drug design of new dual 5HT2A/D2-R antagonists as potentially effective therapeutics of complex neurological and mental disorders
SP  - 125
EP  - 125
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4762
ER  - 
@conference{
author = "Nikolić, Katarina and Radan, Milica and Đikić, Teodora",
year = "2023",
publisher = "European Research Network on Signal Transduction CA18133 (ERNEST)",
journal = "8th and final ERNEST Meeting "GPCR structure and function: The present and perspectives for the future”, May 3-7, 2023 in Crete, Greece",
title = "Polypharmacological strategy in rational drug design of new dual 5HT2A/D2-R antagonists as potentially effective therapeutics of complex neurological and mental disorders",
pages = "125-125",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4762"
}
Nikolić, K., Radan, M.,& Đikić, T.. (2023). Polypharmacological strategy in rational drug design of new dual 5HT2A/D2-R antagonists as potentially effective therapeutics of complex neurological and mental disorders. in 8th and final ERNEST Meeting "GPCR structure and function: The present and perspectives for the future”, May 3-7, 2023 in Crete, Greece
European Research Network on Signal Transduction CA18133 (ERNEST)., 125-125.
https://hdl.handle.net/21.15107/rcub_farfar_4762
Nikolić K, Radan M, Đikić T. Polypharmacological strategy in rational drug design of new dual 5HT2A/D2-R antagonists as potentially effective therapeutics of complex neurological and mental disorders. in 8th and final ERNEST Meeting "GPCR structure and function: The present and perspectives for the future”, May 3-7, 2023 in Crete, Greece. 2023;:125-125.
https://hdl.handle.net/21.15107/rcub_farfar_4762 .
Nikolić, Katarina, Radan, Milica, Đikić, Teodora, "Polypharmacological strategy in rational drug design of new dual 5HT2A/D2-R antagonists as potentially effective therapeutics of complex neurological and mental disorders" in 8th and final ERNEST Meeting "GPCR structure and function: The present and perspectives for the future”, May 3-7, 2023 in Crete, Greece (2023):125-125,
https://hdl.handle.net/21.15107/rcub_farfar_4762 .

SIRT2i_Predictor: A Machine Learning-Based Tool to Facilitate the Discovery of Novel SIRT2 Inhibitors

Đoković, Nemanja; Rahnasto-Rilla, Minna; Lougiakis, Nikolas; Lahtela-Kakkonen, Maija; Nikolić, Katarina

(MDPI, 2023)

TY  - JOUR
AU  - Đoković, Nemanja
AU  - Rahnasto-Rilla, Minna
AU  - Lougiakis, Nikolas
AU  - Lahtela-Kakkonen, Maija
AU  - Nikolić, Katarina
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4416
AB  - A growing body of preclinical evidence recognized selective sirtuin 2 (SIRT2) inhibitors as novel therapeutics for treatment of age-related diseases. However, none of the SIRT2 inhibitors have reached clinical trials yet. Transformative potential of machine learning (ML) in early stages of drug discovery has been witnessed by widespread adoption of these techniques in recent years. Despite great potential, there is a lack of robust and large-scale ML models for discovery of novel SIRT2 inhibitors. In order to support virtual screening (VS), lead optimization, or facilitate the selection of SIRT2 inhibitors for experimental evaluation, a machine-learning-based tool titled SIRT2i_Predictor was developed. The tool was built on a panel of high-quality ML regression and classification-based models for prediction of inhibitor potency and SIRT1-3 isoform selectivity. State-of-the-art ML algorithms were used to train the models on a large and diverse dataset containing 1797 compounds. Benchmarking against structure-based VS protocol indicated comparable coverage of chemical space with great gain in speed. The tool was applied to screen the in-house database of compounds, corroborating the utility in the prioritization of compounds for costly in vitro screening campaigns. The easy-to-use web-based interface makes SIRT2i_Predictor a convenient tool for the wider community. The SIRT2i_Predictor’s source code is made available online.
PB  - MDPI
T2  - Pharmaceuticals
T1  - SIRT2i_Predictor: A Machine Learning-Based Tool to Facilitate the Discovery of Novel SIRT2 Inhibitors
VL  - 16
IS  - 1
DO  - 10.3390/ph16010127
ER  - 
@article{
author = "Đoković, Nemanja and Rahnasto-Rilla, Minna and Lougiakis, Nikolas and Lahtela-Kakkonen, Maija and Nikolić, Katarina",
year = "2023",
abstract = "A growing body of preclinical evidence recognized selective sirtuin 2 (SIRT2) inhibitors as novel therapeutics for treatment of age-related diseases. However, none of the SIRT2 inhibitors have reached clinical trials yet. Transformative potential of machine learning (ML) in early stages of drug discovery has been witnessed by widespread adoption of these techniques in recent years. Despite great potential, there is a lack of robust and large-scale ML models for discovery of novel SIRT2 inhibitors. In order to support virtual screening (VS), lead optimization, or facilitate the selection of SIRT2 inhibitors for experimental evaluation, a machine-learning-based tool titled SIRT2i_Predictor was developed. The tool was built on a panel of high-quality ML regression and classification-based models for prediction of inhibitor potency and SIRT1-3 isoform selectivity. State-of-the-art ML algorithms were used to train the models on a large and diverse dataset containing 1797 compounds. Benchmarking against structure-based VS protocol indicated comparable coverage of chemical space with great gain in speed. The tool was applied to screen the in-house database of compounds, corroborating the utility in the prioritization of compounds for costly in vitro screening campaigns. The easy-to-use web-based interface makes SIRT2i_Predictor a convenient tool for the wider community. The SIRT2i_Predictor’s source code is made available online.",
publisher = "MDPI",
journal = "Pharmaceuticals",
title = "SIRT2i_Predictor: A Machine Learning-Based Tool to Facilitate the Discovery of Novel SIRT2 Inhibitors",
volume = "16",
number = "1",
doi = "10.3390/ph16010127"
}
Đoković, N., Rahnasto-Rilla, M., Lougiakis, N., Lahtela-Kakkonen, M.,& Nikolić, K.. (2023). SIRT2i_Predictor: A Machine Learning-Based Tool to Facilitate the Discovery of Novel SIRT2 Inhibitors. in Pharmaceuticals
MDPI., 16(1).
https://doi.org/10.3390/ph16010127
Đoković N, Rahnasto-Rilla M, Lougiakis N, Lahtela-Kakkonen M, Nikolić K. SIRT2i_Predictor: A Machine Learning-Based Tool to Facilitate the Discovery of Novel SIRT2 Inhibitors. in Pharmaceuticals. 2023;16(1).
doi:10.3390/ph16010127 .
Đoković, Nemanja, Rahnasto-Rilla, Minna, Lougiakis, Nikolas, Lahtela-Kakkonen, Maija, Nikolić, Katarina, "SIRT2i_Predictor: A Machine Learning-Based Tool to Facilitate the Discovery of Novel SIRT2 Inhibitors" in Pharmaceuticals, 16, no. 1 (2023),
https://doi.org/10.3390/ph16010127 . .
5

Screening of naphthalimides as antimetastatic agents

Sánchez-Martín, Victoria; Ružić, Dušan; Castilla-Maldonado, Ignacio; Ortiz-González, Matilde; Soriano-Lerma, Ana; Linde-Rodríguez, Ángel; Pérez-Carrasco, Virginia; Ramirez-Macias, Inmaculada; Soriano, Miguel; Nikolić, Katarina; García-Salcedo, Jose Antonio

(MDPI, 2023)

TY  - CONF
AU  - Sánchez-Martín, Victoria
AU  - Ružić, Dušan
AU  - Castilla-Maldonado, Ignacio
AU  - Ortiz-González, Matilde
AU  - Soriano-Lerma, Ana
AU  - Linde-Rodríguez, Ángel
AU  - Pérez-Carrasco, Virginia
AU  - Ramirez-Macias, Inmaculada
AU  - Soriano, Miguel
AU  - Nikolić, Katarina
AU  - García-Salcedo, Jose Antonio
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4911
AB  - Metastasis is a major problem in the management of cancer, remaining as the principal cause of cancer death. Despite recent advances, treatment options are still limited. Naphthalimide (1H-benzo[de]isoquinoline-1,3-(2H)-dione) analogs have been considered as promising anticancer agents against different tumor types. However, antimetastatic potential of naphthalimides has not been previously established. The aim of this work was to evaluate the possible antimetastatic activ-ity of a panel of 21 naphthalimides which were synthesized in the laboratory. We studied the inhib-itory effects of these compounds on cancer proliferation, clonogenicity and cell cycle progression. We identified 5 naphthalimides with a potent and selective inhibition of growth in SW620 metastatic cells compared to CRL1790 non-tumoral ones. In addition, these 5 naphthalimides induced a sig-nificant arrest at S and G2/M phase in SW620 cells. Finally, we selected the leading compound 20B, which inhibited clonogenic expansion in SW620 cells even at 10 μM. These results shed light on 20B naphthalimide as an emerging antimetastatic agent. Future studies are required to determine its mechanism of action.
PB  - MDPI
C3  - Medical sciences forum
T1  - Screening of naphthalimides as antimetastatic agents
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4911
ER  - 
@conference{
author = "Sánchez-Martín, Victoria and Ružić, Dušan and Castilla-Maldonado, Ignacio and Ortiz-González, Matilde and Soriano-Lerma, Ana and Linde-Rodríguez, Ángel and Pérez-Carrasco, Virginia and Ramirez-Macias, Inmaculada and Soriano, Miguel and Nikolić, Katarina and García-Salcedo, Jose Antonio",
year = "2023",
abstract = "Metastasis is a major problem in the management of cancer, remaining as the principal cause of cancer death. Despite recent advances, treatment options are still limited. Naphthalimide (1H-benzo[de]isoquinoline-1,3-(2H)-dione) analogs have been considered as promising anticancer agents against different tumor types. However, antimetastatic potential of naphthalimides has not been previously established. The aim of this work was to evaluate the possible antimetastatic activ-ity of a panel of 21 naphthalimides which were synthesized in the laboratory. We studied the inhib-itory effects of these compounds on cancer proliferation, clonogenicity and cell cycle progression. We identified 5 naphthalimides with a potent and selective inhibition of growth in SW620 metastatic cells compared to CRL1790 non-tumoral ones. In addition, these 5 naphthalimides induced a sig-nificant arrest at S and G2/M phase in SW620 cells. Finally, we selected the leading compound 20B, which inhibited clonogenic expansion in SW620 cells even at 10 μM. These results shed light on 20B naphthalimide as an emerging antimetastatic agent. Future studies are required to determine its mechanism of action.",
publisher = "MDPI",
journal = "Medical sciences forum",
title = "Screening of naphthalimides as antimetastatic agents",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4911"
}
Sánchez-Martín, V., Ružić, D., Castilla-Maldonado, I., Ortiz-González, M., Soriano-Lerma, A., Linde-Rodríguez, Á., Pérez-Carrasco, V., Ramirez-Macias, I., Soriano, M., Nikolić, K.,& García-Salcedo, J. A.. (2023). Screening of naphthalimides as antimetastatic agents. in Medical sciences forum
MDPI..
https://hdl.handle.net/21.15107/rcub_farfar_4911
Sánchez-Martín V, Ružić D, Castilla-Maldonado I, Ortiz-González M, Soriano-Lerma A, Linde-Rodríguez Á, Pérez-Carrasco V, Ramirez-Macias I, Soriano M, Nikolić K, García-Salcedo JA. Screening of naphthalimides as antimetastatic agents. in Medical sciences forum. 2023;.
https://hdl.handle.net/21.15107/rcub_farfar_4911 .
Sánchez-Martín, Victoria, Ružić, Dušan, Castilla-Maldonado, Ignacio, Ortiz-González, Matilde, Soriano-Lerma, Ana, Linde-Rodríguez, Ángel, Pérez-Carrasco, Virginia, Ramirez-Macias, Inmaculada, Soriano, Miguel, Nikolić, Katarina, García-Salcedo, Jose Antonio, "Screening of naphthalimides as antimetastatic agents" in Medical sciences forum (2023),
https://hdl.handle.net/21.15107/rcub_farfar_4911 .

Discovery of novel small molecule inhibitors of HDAC6 that suppress liver fibrosis

Borrello, Maria Teresa; Ružić, Dušan; Oakley, Fiona; Nikolić, Katarina; Mann, Jelena; Mann, Derek

(Elsevire, 2023)

TY  - CONF
AU  - Borrello, Maria Teresa
AU  - Ružić, Dušan
AU  - Oakley, Fiona
AU  - Nikolić, Katarina
AU  - Mann, Jelena
AU  - Mann, Derek
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4912
PB  - Elsevire
C3  - Journal of Hepatology
T1  - Discovery of novel small molecule inhibitors of HDAC6 that suppress liver fibrosis
VL  - 78
IS  - S1
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4912
ER  - 
@conference{
author = "Borrello, Maria Teresa and Ružić, Dušan and Oakley, Fiona and Nikolić, Katarina and Mann, Jelena and Mann, Derek",
year = "2023",
publisher = "Elsevire",
journal = "Journal of Hepatology",
title = "Discovery of novel small molecule inhibitors of HDAC6 that suppress liver fibrosis",
volume = "78",
number = "S1",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4912"
}
Borrello, M. T., Ružić, D., Oakley, F., Nikolić, K., Mann, J.,& Mann, D.. (2023). Discovery of novel small molecule inhibitors of HDAC6 that suppress liver fibrosis. in Journal of Hepatology
Elsevire., 78(S1).
https://hdl.handle.net/21.15107/rcub_farfar_4912
Borrello MT, Ružić D, Oakley F, Nikolić K, Mann J, Mann D. Discovery of novel small molecule inhibitors of HDAC6 that suppress liver fibrosis. in Journal of Hepatology. 2023;78(S1).
https://hdl.handle.net/21.15107/rcub_farfar_4912 .
Borrello, Maria Teresa, Ružić, Dušan, Oakley, Fiona, Nikolić, Katarina, Mann, Jelena, Mann, Derek, "Discovery of novel small molecule inhibitors of HDAC6 that suppress liver fibrosis" in Journal of Hepatology, 78, no. S1 (2023),
https://hdl.handle.net/21.15107/rcub_farfar_4912 .

Design of experiments and Derringer's desirability function in optimisation and validation of RP-HPLC method for the analysis of enrofloxacin and its impurities

Dokmanović, Jelena; Kasagić-Vujanović, Irena; Gagić, Žarko; Nikolić, Katarina; Čarapić, Marija; Agbaba, Danica

(Akademiai Kiado ZRt., 2023)

TY  - JOUR
AU  - Dokmanović, Jelena
AU  - Kasagić-Vujanović, Irena
AU  - Gagić, Žarko
AU  - Nikolić, Katarina
AU  - Čarapić, Marija
AU  - Agbaba, Danica
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4474
AB  - Using the Design of Experiments methodology (Response-Surface Methodology and Derringer's Desirability Function), a simple, fast and robust RP-HPLC method was developed for the analysis of enrofloxacin (EFC), its impurity A (fluoroquinolonic acid, FQ) and impurity B (ciprofloxacin, CPX). Gradient elution of samples was performed on a Zorbax Eclipse XDB C18 column (150 × 4.6 mm, 3.5 μm) with a mobile phase consisting of 32 mM phosphate buffer pH 3.5-methanol (0 min-19.6% methanol; 15.5 min-19.6% methanol; 29.5 min-80% methanol; 30 min-19.6% methanol; 35 min-19.6% methanol), delivered at a flow rate of 1.5 mL min-1, wavelength of detection 278 nm (for EFX and CFX) and 265 nm for FQ. A good linear response was achieved in the range 15-35 μg mL-1 (EFX) and LOQ-150% for impurities (CFX and FQ). Other validation parameters were also tested: precision, accuracy, sensitivity and robustness. The developed method was shown to be simple, practical and suitable for the analysis of EFC and its impurities (CPX, FQ) in veterinary drugs.
PB  - Akademiai Kiado ZRt.
T2  - Acta Chromatographica
T1  - Design of experiments and Derringer's desirability function in optimisation and validation of RP-HPLC method for the analysis of enrofloxacin and its impurities
DO  - 10.1556/1326.2022.01111
ER  - 
@article{
author = "Dokmanović, Jelena and Kasagić-Vujanović, Irena and Gagić, Žarko and Nikolić, Katarina and Čarapić, Marija and Agbaba, Danica",
year = "2023",
abstract = "Using the Design of Experiments methodology (Response-Surface Methodology and Derringer's Desirability Function), a simple, fast and robust RP-HPLC method was developed for the analysis of enrofloxacin (EFC), its impurity A (fluoroquinolonic acid, FQ) and impurity B (ciprofloxacin, CPX). Gradient elution of samples was performed on a Zorbax Eclipse XDB C18 column (150 × 4.6 mm, 3.5 μm) with a mobile phase consisting of 32 mM phosphate buffer pH 3.5-methanol (0 min-19.6% methanol; 15.5 min-19.6% methanol; 29.5 min-80% methanol; 30 min-19.6% methanol; 35 min-19.6% methanol), delivered at a flow rate of 1.5 mL min-1, wavelength of detection 278 nm (for EFX and CFX) and 265 nm for FQ. A good linear response was achieved in the range 15-35 μg mL-1 (EFX) and LOQ-150% for impurities (CFX and FQ). Other validation parameters were also tested: precision, accuracy, sensitivity and robustness. The developed method was shown to be simple, practical and suitable for the analysis of EFC and its impurities (CPX, FQ) in veterinary drugs.",
publisher = "Akademiai Kiado ZRt.",
journal = "Acta Chromatographica",
title = "Design of experiments and Derringer's desirability function in optimisation and validation of RP-HPLC method for the analysis of enrofloxacin and its impurities",
doi = "10.1556/1326.2022.01111"
}
Dokmanović, J., Kasagić-Vujanović, I., Gagić, Ž., Nikolić, K., Čarapić, M.,& Agbaba, D.. (2023). Design of experiments and Derringer's desirability function in optimisation and validation of RP-HPLC method for the analysis of enrofloxacin and its impurities. in Acta Chromatographica
Akademiai Kiado ZRt...
https://doi.org/10.1556/1326.2022.01111
Dokmanović J, Kasagić-Vujanović I, Gagić Ž, Nikolić K, Čarapić M, Agbaba D. Design of experiments and Derringer's desirability function in optimisation and validation of RP-HPLC method for the analysis of enrofloxacin and its impurities. in Acta Chromatographica. 2023;.
doi:10.1556/1326.2022.01111 .
Dokmanović, Jelena, Kasagić-Vujanović, Irena, Gagić, Žarko, Nikolić, Katarina, Čarapić, Marija, Agbaba, Danica, "Design of experiments and Derringer's desirability function in optimisation and validation of RP-HPLC method for the analysis of enrofloxacin and its impurities" in Acta Chromatographica (2023),
https://doi.org/10.1556/1326.2022.01111 . .

The evaluation of drug-plasma protein binding interaction on immobilized human serum albumin stationary phase, aided by different computational approaches

Obradović, Darija; Radan, Milica; Đikić, Teodora; Popović-Nikolić, Marija; Oljačić, Slavica; Nikolić, Katarina

(Elsevier B.V., 2022)

TY  - JOUR
AU  - Obradović, Darija
AU  - Radan, Milica
AU  - Đikić, Teodora
AU  - Popović-Nikolić, Marija
AU  - Oljačić, Slavica
AU  - Nikolić, Katarina
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4045
AB  - The drug-human serum albumin binding interaction was evaluated on a stationary phase immobilized with human serum albumin using a mixture of phosphate buffer (pH 7.0) and acetonitrile modifier as mobile phase. The 33 compounds that have a wide structural and therapeutic diversity were analyzed by per- forming a large number of experiments. The interaction mechanism was interpreted based on: i) retention characteristics of structurally related compounds, ii) retention modeling, iii) quantitative structure reten- tion relationship (QSRR), and iv) molecular docking. Small structural differences of related compounds (e.g., reflected in different lipophilicity and polarity) have been found to affect their different binding to human serum albumin. It was found that drug retention in HSA column can be successfully described by using the quadratic function. The isocratic (logk(14%)) and extrapolated (b0(LSS)) retention factors showed the highest correlation (r > 0.76) with the constant that defines the binding affinity for human serum albumin (ACD/I- Lab). Therefore, selected chromatographic parameters can demonstrate reliable applicability for rapid screening of drug-plasma protein binding in drug discovery. In QSRR study, the resulting SVM/logk(14%) and MLR/b0(LSS) models display high internal and external predictive power. The constitutional properties (double bonds, aromatic rings, benzyl, allyl, -amino and -sulfur containing functional groups) supported by the charged parts of surface area had a significant impact on human serum albumin-binding affinity, which was also confirmed with molecular docking study. The high structural diversity of the data set provides wide applicability of tested chromatographic conditions and constructed models for defining the phar- macokinetic profile and possible structural modifications that can increase plasma protein binding of newly synthesized, pharmaceutically important compounds.
PB  - Elsevier B.V.
T2  - Journal of Pharmaceutical and Biomedical Analysis
T1  - The evaluation of drug-plasma protein binding interaction on immobilized human serum albumin stationary phase, aided by different computational approaches
VL  - 211
DO  - 10.1016/j.jpba.2022.114593
ER  - 
@article{
author = "Obradović, Darija and Radan, Milica and Đikić, Teodora and Popović-Nikolić, Marija and Oljačić, Slavica and Nikolić, Katarina",
year = "2022",
abstract = "The drug-human serum albumin binding interaction was evaluated on a stationary phase immobilized with human serum albumin using a mixture of phosphate buffer (pH 7.0) and acetonitrile modifier as mobile phase. The 33 compounds that have a wide structural and therapeutic diversity were analyzed by per- forming a large number of experiments. The interaction mechanism was interpreted based on: i) retention characteristics of structurally related compounds, ii) retention modeling, iii) quantitative structure reten- tion relationship (QSRR), and iv) molecular docking. Small structural differences of related compounds (e.g., reflected in different lipophilicity and polarity) have been found to affect their different binding to human serum albumin. It was found that drug retention in HSA column can be successfully described by using the quadratic function. The isocratic (logk(14%)) and extrapolated (b0(LSS)) retention factors showed the highest correlation (r > 0.76) with the constant that defines the binding affinity for human serum albumin (ACD/I- Lab). Therefore, selected chromatographic parameters can demonstrate reliable applicability for rapid screening of drug-plasma protein binding in drug discovery. In QSRR study, the resulting SVM/logk(14%) and MLR/b0(LSS) models display high internal and external predictive power. The constitutional properties (double bonds, aromatic rings, benzyl, allyl, -amino and -sulfur containing functional groups) supported by the charged parts of surface area had a significant impact on human serum albumin-binding affinity, which was also confirmed with molecular docking study. The high structural diversity of the data set provides wide applicability of tested chromatographic conditions and constructed models for defining the phar- macokinetic profile and possible structural modifications that can increase plasma protein binding of newly synthesized, pharmaceutically important compounds.",
publisher = "Elsevier B.V.",
journal = "Journal of Pharmaceutical and Biomedical Analysis",
title = "The evaluation of drug-plasma protein binding interaction on immobilized human serum albumin stationary phase, aided by different computational approaches",
volume = "211",
doi = "10.1016/j.jpba.2022.114593"
}
Obradović, D., Radan, M., Đikić, T., Popović-Nikolić, M., Oljačić, S.,& Nikolić, K.. (2022). The evaluation of drug-plasma protein binding interaction on immobilized human serum albumin stationary phase, aided by different computational approaches. in Journal of Pharmaceutical and Biomedical Analysis
Elsevier B.V.., 211.
https://doi.org/10.1016/j.jpba.2022.114593
Obradović D, Radan M, Đikić T, Popović-Nikolić M, Oljačić S, Nikolić K. The evaluation of drug-plasma protein binding interaction on immobilized human serum albumin stationary phase, aided by different computational approaches. in Journal of Pharmaceutical and Biomedical Analysis. 2022;211.
doi:10.1016/j.jpba.2022.114593 .
Obradović, Darija, Radan, Milica, Đikić, Teodora, Popović-Nikolić, Marija, Oljačić, Slavica, Nikolić, Katarina, "The evaluation of drug-plasma protein binding interaction on immobilized human serum albumin stationary phase, aided by different computational approaches" in Journal of Pharmaceutical and Biomedical Analysis, 211 (2022),
https://doi.org/10.1016/j.jpba.2022.114593 . .
4
4

Characterization of unknown degradant of ziprasidone with NMR spetroscopy

Čarapić, Marija; Petković, Miloš; Marković, Bojan; Popović-Nikolić, Marija; Agbaba, Danica; Nikolić, Katarina

(Society of Physical Chemists of Serbia, 2022)

TY  - CONF
AU  - Čarapić, Marija
AU  - Petković, Miloš
AU  - Marković, Bojan
AU  - Popović-Nikolić, Marija
AU  - Agbaba, Danica
AU  - Nikolić, Katarina
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4684
AB  - Ziprasidone (ZIP) is the second generation antipsychotic drug with unique G-protein-coupled
(GPCR) receptor binding profile. It is a highly lipophilic and unstable compound. Our group
developed and validated the single liquid chromatographic (LC) system for simultaneous
determination of ZIP and its five main impurities (IMPs) and we modelled the Quantitative
Structure Retention Relationship (QSRR) of the additional ten compounds including unknown
detected degradant. One of two proposed structures were confirmed by UPLC-MS/MS study. The
further characterisation of unknown degradant was performed with NMR studies as un versatile
tool for characterisation of each compound and it is presented. Through several experiments which consists of investigation of chemical shitfs in NMR spectra of ZIP degradation products the
structure of unknown degradant was proposed and confirmed as in previous experiments.
PB  - Society of Physical Chemists of Serbia
C3  - PHYSICAL CHEMISTRY 2022, 16th International Conference on Fundamental and Applied Aspects of Physical Chemistry (Proceedings)
T1  - Characterization of unknown degradant of ziprasidone with NMR spetroscopy
VL  - II
SP  - 601
EP  - 604
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4684
ER  - 
@conference{
author = "Čarapić, Marija and Petković, Miloš and Marković, Bojan and Popović-Nikolić, Marija and Agbaba, Danica and Nikolić, Katarina",
year = "2022",
abstract = "Ziprasidone (ZIP) is the second generation antipsychotic drug with unique G-protein-coupled
(GPCR) receptor binding profile. It is a highly lipophilic and unstable compound. Our group
developed and validated the single liquid chromatographic (LC) system for simultaneous
determination of ZIP and its five main impurities (IMPs) and we modelled the Quantitative
Structure Retention Relationship (QSRR) of the additional ten compounds including unknown
detected degradant. One of two proposed structures were confirmed by UPLC-MS/MS study. The
further characterisation of unknown degradant was performed with NMR studies as un versatile
tool for characterisation of each compound and it is presented. Through several experiments which consists of investigation of chemical shitfs in NMR spectra of ZIP degradation products the
structure of unknown degradant was proposed and confirmed as in previous experiments.",
publisher = "Society of Physical Chemists of Serbia",
journal = "PHYSICAL CHEMISTRY 2022, 16th International Conference on Fundamental and Applied Aspects of Physical Chemistry (Proceedings)",
title = "Characterization of unknown degradant of ziprasidone with NMR spetroscopy",
volume = "II",
pages = "601-604",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4684"
}
Čarapić, M., Petković, M., Marković, B., Popović-Nikolić, M., Agbaba, D.,& Nikolić, K.. (2022). Characterization of unknown degradant of ziprasidone with NMR spetroscopy. in PHYSICAL CHEMISTRY 2022, 16th International Conference on Fundamental and Applied Aspects of Physical Chemistry (Proceedings)
Society of Physical Chemists of Serbia., II, 601-604.
https://hdl.handle.net/21.15107/rcub_farfar_4684
Čarapić M, Petković M, Marković B, Popović-Nikolić M, Agbaba D, Nikolić K. Characterization of unknown degradant of ziprasidone with NMR spetroscopy. in PHYSICAL CHEMISTRY 2022, 16th International Conference on Fundamental and Applied Aspects of Physical Chemistry (Proceedings). 2022;II:601-604.
https://hdl.handle.net/21.15107/rcub_farfar_4684 .
Čarapić, Marija, Petković, Miloš, Marković, Bojan, Popović-Nikolić, Marija, Agbaba, Danica, Nikolić, Katarina, "Characterization of unknown degradant of ziprasidone with NMR spetroscopy" in PHYSICAL CHEMISTRY 2022, 16th International Conference on Fundamental and Applied Aspects of Physical Chemistry (Proceedings), II (2022):601-604,
https://hdl.handle.net/21.15107/rcub_farfar_4684 .

The ionization of pharmacologically active compounds in the presence of differently charged micelles as biomembrane mimetic systems

Popović-Nikolić, Marija; Nikolić, Katarina; Popović, Gordana

(Savez farmaceutskih udruženja Srbije (SFUS), 2022)

TY  - CONF
AU  - Popović-Nikolić, Marija
AU  - Nikolić, Katarina
AU  - Popović, Gordana
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4597
AB  - The knowledge of drugs ionization is necessary for prediction of their pharmacological
behavior and pharmacokinetic parameters (1). However, the distribution of equilibrium forms
could differ from expected one if the estimation is made exclusively based on pKa vales observed
in “pure” water. It is necessary to investigate the ionization of drugs in conditions which is known
to mimic the biological membranes such as the micellar solutions of surfactants (2). The pKa
values of pharmacologically active compounds (antihypertensives, antimicrobial drugs,
antihistamines) have been potentiometrically determined under the same conditions (25 °C, ionic
strength 0.1 M NaCl) with and without micelles, anionic (SDS), cationic (CTAB), nonionic (TX-
100, Brij 35). Experimental results were analyzed in program Hyperquad. Significant shift in
protolytic equilibria (∆pKa) were observed for aliphatic amino (-2.80 to +0.87), aromatic amino (-
1.99 to +1.44), and carboxylic (-0.92 to +1.90) functional groups. The anionic and cationic
expressed higher effect on ionization comparing to nonionic micelles. The presence of micelles
caused the change in distribution of equilibrium forms especially on pH values of
biopharmaceutical importance where the content of ionized form was changed in range from -74%
to +66% comparing to “pure” water. The ionization groups of drugs are involved in interactions
with charged or polar surface of micelles which could be observed in terms of physiological
conditions. Result showed that general pattern of ionization of drugs in micellar media could not
be anticipated so it is necessary to be experimentally investigated for each individual drug.
AB  - Ispitivanje jonizacije lekova neophodno je za predviđanje farmakološkog ponašanja i
farmakokinetičkih parametara (1). Međutim, raspodela ravnotežnih oblika može biti
drugačija od očekivane ako se procena izvodi samo na osnovu pKa vrednosti definisanih
isključivo u “čistoj” vodi. Zato je potrebno ispitati jonizaciju lekova i u uslovima koji
simuliraju prisustvo bioloških membrana, kao što su micelarni rastvori surfaktanata (2). U
ovoj studiji, pKa vrednosti farmakološki aktivnih jedinjenja (antihipertenzivi, antimikrobni
lekovi, antihistaminici), bez i u prisustvu anjonskih (SDS), katjonskih (CTAB) i nejonskih (TX-
100, Brij 35) micela, određene su potenciometrijski, pod istim eksperimentalnim uslovima
(temperatura 25°C i jonska sila 0,1 M NaCl). Eksperimentalni rezultati analizirani su u
programu Hyperquad. Značajna pomeranja protolitičkih ravnoteža (∆pKa) uočena su u
slučaju aromatične amino (od -1,99 do +1,44), alifatične amino (od -2,80 do +0,87) i
karboksilne grupe (od -0,92 do +1,90). Izraženiji uticaj na promenu jonizacije uočen je u
prisustvu anjonskih i katjonskih u odnosu na nejonske micele. Promena raspodele
ravnotežnih oblika u prisustvu micela zapažena je na biofarmaceutski značajnim pH
vrednostima (1,2; 4,5; 6,8; 7,4), pri čemu je sadržaj jonizovanih formi promenjen u opsegu od
-74% do +66% u odnosu na “čistu” vodu. Rezultati pokazuju da se jonizacione grupe lekova
uključuju u interakcije sa polarnom ili naelektrisanom površinom micela što se može
potencijalno razmatrati u kontekstu uticaja na jonizaciju u fiziološkom uslovima. Nije uočen
uopšten obrazac jonizacije lekova u micelarnoj sredini iz čega sledi da je neophodno
eksperimentalno ispitati jonizaciju svakog pojedinačnog jedinjenja u prisustvu micela.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - The ionization of pharmacologically active compounds in the presence of differently charged micelles as biomembrane mimetic systems
T1  - Jonizacija farmakološki aktivnih jedinjenja u micelarnim rastvorima različitog naelektrisanja kao simulirajućih sistema biomembrana
VL  - 72
IS  - 4 suplement
SP  - S530
EP  - S531
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4597
ER  - 
@conference{
author = "Popović-Nikolić, Marija and Nikolić, Katarina and Popović, Gordana",
year = "2022",
abstract = "The knowledge of drugs ionization is necessary for prediction of their pharmacological
behavior and pharmacokinetic parameters (1). However, the distribution of equilibrium forms
could differ from expected one if the estimation is made exclusively based on pKa vales observed
in “pure” water. It is necessary to investigate the ionization of drugs in conditions which is known
to mimic the biological membranes such as the micellar solutions of surfactants (2). The pKa
values of pharmacologically active compounds (antihypertensives, antimicrobial drugs,
antihistamines) have been potentiometrically determined under the same conditions (25 °C, ionic
strength 0.1 M NaCl) with and without micelles, anionic (SDS), cationic (CTAB), nonionic (TX-
100, Brij 35). Experimental results were analyzed in program Hyperquad. Significant shift in
protolytic equilibria (∆pKa) were observed for aliphatic amino (-2.80 to +0.87), aromatic amino (-
1.99 to +1.44), and carboxylic (-0.92 to +1.90) functional groups. The anionic and cationic
expressed higher effect on ionization comparing to nonionic micelles. The presence of micelles
caused the change in distribution of equilibrium forms especially on pH values of
biopharmaceutical importance where the content of ionized form was changed in range from -74%
to +66% comparing to “pure” water. The ionization groups of drugs are involved in interactions
with charged or polar surface of micelles which could be observed in terms of physiological
conditions. Result showed that general pattern of ionization of drugs in micellar media could not
be anticipated so it is necessary to be experimentally investigated for each individual drug., Ispitivanje jonizacije lekova neophodno je za predviđanje farmakološkog ponašanja i
farmakokinetičkih parametara (1). Međutim, raspodela ravnotežnih oblika može biti
drugačija od očekivane ako se procena izvodi samo na osnovu pKa vrednosti definisanih
isključivo u “čistoj” vodi. Zato je potrebno ispitati jonizaciju lekova i u uslovima koji
simuliraju prisustvo bioloških membrana, kao što su micelarni rastvori surfaktanata (2). U
ovoj studiji, pKa vrednosti farmakološki aktivnih jedinjenja (antihipertenzivi, antimikrobni
lekovi, antihistaminici), bez i u prisustvu anjonskih (SDS), katjonskih (CTAB) i nejonskih (TX-
100, Brij 35) micela, određene su potenciometrijski, pod istim eksperimentalnim uslovima
(temperatura 25°C i jonska sila 0,1 M NaCl). Eksperimentalni rezultati analizirani su u
programu Hyperquad. Značajna pomeranja protolitičkih ravnoteža (∆pKa) uočena su u
slučaju aromatične amino (od -1,99 do +1,44), alifatične amino (od -2,80 do +0,87) i
karboksilne grupe (od -0,92 do +1,90). Izraženiji uticaj na promenu jonizacije uočen je u
prisustvu anjonskih i katjonskih u odnosu na nejonske micele. Promena raspodele
ravnotežnih oblika u prisustvu micela zapažena je na biofarmaceutski značajnim pH
vrednostima (1,2; 4,5; 6,8; 7,4), pri čemu je sadržaj jonizovanih formi promenjen u opsegu od
-74% do +66% u odnosu na “čistu” vodu. Rezultati pokazuju da se jonizacione grupe lekova
uključuju u interakcije sa polarnom ili naelektrisanom površinom micela što se može
potencijalno razmatrati u kontekstu uticaja na jonizaciju u fiziološkom uslovima. Nije uočen
uopšten obrazac jonizacije lekova u micelarnoj sredini iz čega sledi da je neophodno
eksperimentalno ispitati jonizaciju svakog pojedinačnog jedinjenja u prisustvu micela.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "The ionization of pharmacologically active compounds in the presence of differently charged micelles as biomembrane mimetic systems, Jonizacija farmakološki aktivnih jedinjenja u micelarnim rastvorima različitog naelektrisanja kao simulirajućih sistema biomembrana",
volume = "72",
number = "4 suplement",
pages = "S530-S531",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4597"
}
Popović-Nikolić, M., Nikolić, K.,& Popović, G.. (2022). The ionization of pharmacologically active compounds in the presence of differently charged micelles as biomembrane mimetic systems. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S530-S531.
https://hdl.handle.net/21.15107/rcub_farfar_4597
Popović-Nikolić M, Nikolić K, Popović G. The ionization of pharmacologically active compounds in the presence of differently charged micelles as biomembrane mimetic systems. in Arhiv za farmaciju. 2022;72(4 suplement):S530-S531.
https://hdl.handle.net/21.15107/rcub_farfar_4597 .
Popović-Nikolić, Marija, Nikolić, Katarina, Popović, Gordana, "The ionization of pharmacologically active compounds in the presence of differently charged micelles as biomembrane mimetic systems" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S530-S531,
https://hdl.handle.net/21.15107/rcub_farfar_4597 .

Bistable Photoswitch Allows in Vivo Control of Hematopoiesis

Albert, Lea; Nagpal, Jatin; Steinchen, Wieland; Zhang, Lei; Werel, Laura; Đoković, Nemanja; Ružić, Dušan; Hoffarth, Malte; Xu, Jing; Kaspareit, Johanna; Abendroth, Frank; Royant, Antoine; Bange, Gert; Nikolić, Katarina; Ryu, Soojin; Dou, Yali; Essen, Lars-Oliver; Vázquez, Olalla

(American Chemical Society, 2022)

TY  - JOUR
AU  - Albert, Lea
AU  - Nagpal, Jatin
AU  - Steinchen, Wieland
AU  - Zhang, Lei
AU  - Werel, Laura
AU  - Đoković, Nemanja
AU  - Ružić, Dušan
AU  - Hoffarth, Malte
AU  - Xu, Jing
AU  - Kaspareit, Johanna
AU  - Abendroth, Frank
AU  - Royant, Antoine
AU  - Bange, Gert
AU  - Nikolić, Katarina
AU  - Ryu, Soojin
AU  - Dou, Yali
AU  - Essen, Lars-Oliver
AU  - Vázquez, Olalla
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4904
AB  - Optical control has enabled functional modulation
in cell culture with unparalleled spatiotemporal resolution.
However, current tools for in vivo manipulation are scarce. Here,
we design and implement a genuine on−of f optochemical probe
capable of achieving hematopoietic control in zebrafish. Our
photopharmacological approach first developed conformationally
strained visible light photoswitches (CS-VIPs) as inhibitors of the
histone methyltransferase MLL1 (KMT2A). In blood homeostasis
MLL1 plays a crucial yet controversial role. CS-VIP 8 optimally
fulfils the requirements of a true bistable functional system in vivo under visible-light irradiation, and with unprecedented stability.
These properties are exemplified via hematopoiesis photoinhibition with a single isomer in zebrafish. The present interdisciplinary
study uncovers the mechanism of action of CS-VIPs. Upon WDR5 binding, CS-VIP 8 causes MLL1 release with concomitant
allosteric rearrangements in the WDR5/RbBP5 interface. Since our tool provides on-demand reversible control without genetic
intervention or continuous irradiation, it will foster hematopathology and epigenetic investigations. Furthermore, our workflow will
enable exquisite photocontrol over other targets inhibited by macrocycles.
PB  - American Chemical Society
T2  - ACS Central Science
T1  - Bistable Photoswitch Allows in Vivo Control of Hematopoiesis
VL  - 8
IS  - 1
SP  - 57
EP  - 66
DO  - 10.1021/acscentsci.1c00434
ER  - 
@article{
author = "Albert, Lea and Nagpal, Jatin and Steinchen, Wieland and Zhang, Lei and Werel, Laura and Đoković, Nemanja and Ružić, Dušan and Hoffarth, Malte and Xu, Jing and Kaspareit, Johanna and Abendroth, Frank and Royant, Antoine and Bange, Gert and Nikolić, Katarina and Ryu, Soojin and Dou, Yali and Essen, Lars-Oliver and Vázquez, Olalla",
year = "2022",
abstract = "Optical control has enabled functional modulation
in cell culture with unparalleled spatiotemporal resolution.
However, current tools for in vivo manipulation are scarce. Here,
we design and implement a genuine on−of f optochemical probe
capable of achieving hematopoietic control in zebrafish. Our
photopharmacological approach first developed conformationally
strained visible light photoswitches (CS-VIPs) as inhibitors of the
histone methyltransferase MLL1 (KMT2A). In blood homeostasis
MLL1 plays a crucial yet controversial role. CS-VIP 8 optimally
fulfils the requirements of a true bistable functional system in vivo under visible-light irradiation, and with unprecedented stability.
These properties are exemplified via hematopoiesis photoinhibition with a single isomer in zebrafish. The present interdisciplinary
study uncovers the mechanism of action of CS-VIPs. Upon WDR5 binding, CS-VIP 8 causes MLL1 release with concomitant
allosteric rearrangements in the WDR5/RbBP5 interface. Since our tool provides on-demand reversible control without genetic
intervention or continuous irradiation, it will foster hematopathology and epigenetic investigations. Furthermore, our workflow will
enable exquisite photocontrol over other targets inhibited by macrocycles.",
publisher = "American Chemical Society",
journal = "ACS Central Science",
title = "Bistable Photoswitch Allows in Vivo Control of Hematopoiesis",
volume = "8",
number = "1",
pages = "57-66",
doi = "10.1021/acscentsci.1c00434"
}
Albert, L., Nagpal, J., Steinchen, W., Zhang, L., Werel, L., Đoković, N., Ružić, D., Hoffarth, M., Xu, J., Kaspareit, J., Abendroth, F., Royant, A., Bange, G., Nikolić, K., Ryu, S., Dou, Y., Essen, L.,& Vázquez, O.. (2022). Bistable Photoswitch Allows in Vivo Control of Hematopoiesis. in ACS Central Science
American Chemical Society., 8(1), 57-66.
https://doi.org/10.1021/acscentsci.1c00434
Albert L, Nagpal J, Steinchen W, Zhang L, Werel L, Đoković N, Ružić D, Hoffarth M, Xu J, Kaspareit J, Abendroth F, Royant A, Bange G, Nikolić K, Ryu S, Dou Y, Essen L, Vázquez O. Bistable Photoswitch Allows in Vivo Control of Hematopoiesis. in ACS Central Science. 2022;8(1):57-66.
doi:10.1021/acscentsci.1c00434 .
Albert, Lea, Nagpal, Jatin, Steinchen, Wieland, Zhang, Lei, Werel, Laura, Đoković, Nemanja, Ružić, Dušan, Hoffarth, Malte, Xu, Jing, Kaspareit, Johanna, Abendroth, Frank, Royant, Antoine, Bange, Gert, Nikolić, Katarina, Ryu, Soojin, Dou, Yali, Essen, Lars-Oliver, Vázquez, Olalla, "Bistable Photoswitch Allows in Vivo Control of Hematopoiesis" in ACS Central Science, 8, no. 1 (2022):57-66,
https://doi.org/10.1021/acscentsci.1c00434 . .
22
7
6

Quinazoline-based analog of adenine as an antidote against MLL-rearranged leukemia cells: synthesis, inhibition assays and docking studies

Bon, Corentin; Barbachowska, Magdalena; Đoković, Nemanja; Ružić, Dušan; Si, Yang; Soresinetti, Laura; Jallet, Corinne; Tafit, Ambre; Halby, Ludovic; Nikolić, Katarina; Arimondo, Paola B

(Newlands Press, 2022)

TY  - JOUR
AU  - Bon, Corentin
AU  - Barbachowska, Magdalena
AU  - Đoković, Nemanja
AU  - Ružić, Dušan
AU  - Si, Yang
AU  - Soresinetti, Laura
AU  - Jallet, Corinne
AU  - Tafit, Ambre
AU  - Halby, Ludovic
AU  - Nikolić, Katarina
AU  - Arimondo, Paola B
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4908
AB  - Post-translational modifications of histones constitute a dynamic process impacting gene expression. A well-studied modification is lysine methylation. Among the lysine histone methyltransferases, DOT1L is implicated in various diseases, making it a very interesting target for drug discovery. DOT1L has two substrates, the SAM cofactor that gives the methyl group and the lysine H3K79 substrate. Results: Using molecular docking, the authors explored new bisubstrate analogs to enlarge the chemical landscape of DOT1L inhibitors. The authors showed that quinazoline can successfully replace the adenine in the design of bisubstrate inhibitors of DOT1L, showing similar activity compared with the adenine derivative but with diminished cytotoxicity. Conclusion: The docking model is validated together with the use of quinazoline in the design of bisubstrate inhibitors.
PB  - Newlands Press
T2  - Future Medicinal Chemistry
T1  - Quinazoline-based analog of adenine as an antidote against MLL-rearranged leukemia cells: synthesis, inhibition assays and docking studies
VL  - 14
VL  - 557
VL  - 570
IS  - 8
DO  - 10.4155/fmc-2021-0251
ER  - 
@article{
author = "Bon, Corentin and Barbachowska, Magdalena and Đoković, Nemanja and Ružić, Dušan and Si, Yang and Soresinetti, Laura and Jallet, Corinne and Tafit, Ambre and Halby, Ludovic and Nikolić, Katarina and Arimondo, Paola B",
year = "2022",
abstract = "Post-translational modifications of histones constitute a dynamic process impacting gene expression. A well-studied modification is lysine methylation. Among the lysine histone methyltransferases, DOT1L is implicated in various diseases, making it a very interesting target for drug discovery. DOT1L has two substrates, the SAM cofactor that gives the methyl group and the lysine H3K79 substrate. Results: Using molecular docking, the authors explored new bisubstrate analogs to enlarge the chemical landscape of DOT1L inhibitors. The authors showed that quinazoline can successfully replace the adenine in the design of bisubstrate inhibitors of DOT1L, showing similar activity compared with the adenine derivative but with diminished cytotoxicity. Conclusion: The docking model is validated together with the use of quinazoline in the design of bisubstrate inhibitors.",
publisher = "Newlands Press",
journal = "Future Medicinal Chemistry",
title = "Quinazoline-based analog of adenine as an antidote against MLL-rearranged leukemia cells: synthesis, inhibition assays and docking studies",
volume = "14, 557, 570",
number = "8",
doi = "10.4155/fmc-2021-0251"
}
Bon, C., Barbachowska, M., Đoković, N., Ružić, D., Si, Y., Soresinetti, L., Jallet, C., Tafit, A., Halby, L., Nikolić, K.,& Arimondo, P. B.. (2022). Quinazoline-based analog of adenine as an antidote against MLL-rearranged leukemia cells: synthesis, inhibition assays and docking studies. in Future Medicinal Chemistry
Newlands Press., 14(8).
https://doi.org/10.4155/fmc-2021-0251
Bon C, Barbachowska M, Đoković N, Ružić D, Si Y, Soresinetti L, Jallet C, Tafit A, Halby L, Nikolić K, Arimondo PB. Quinazoline-based analog of adenine as an antidote against MLL-rearranged leukemia cells: synthesis, inhibition assays and docking studies. in Future Medicinal Chemistry. 2022;14(8).
doi:10.4155/fmc-2021-0251 .
Bon, Corentin, Barbachowska, Magdalena, Đoković, Nemanja, Ružić, Dušan, Si, Yang, Soresinetti, Laura, Jallet, Corinne, Tafit, Ambre, Halby, Ludovic, Nikolić, Katarina, Arimondo, Paola B, "Quinazoline-based analog of adenine as an antidote against MLL-rearranged leukemia cells: synthesis, inhibition assays and docking studies" in Future Medicinal Chemistry, 14, no. 8 (2022),
https://doi.org/10.4155/fmc-2021-0251 . .
2

Identification of novel 1-benzhydryl-piperazine derivatives as Histone Deacetylase inhibitors using Fragment-based drug design strategy

Ružić, Dušan; Ellinger, Bernhard; Đoković, Nemanja; Santibanez, Juan; Ganesan, A.; Pavić, Aleksandar; Srdić Rajić, Tatjana; Petković, Miloš; Nikolić, Katarina

(Institute Pasteur, France, 2022)

TY  - GEN
AU  - Ružić, Dušan
AU  - Ellinger, Bernhard
AU  - Đoković, Nemanja
AU  - Santibanez, Juan
AU  - Ganesan, A.
AU  - Pavić, Aleksandar
AU  - Srdić Rajić, Tatjana
AU  - Petković, Miloš
AU  - Nikolić, Katarina
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4951
PB  - Institute Pasteur, France
T2  - Journal Club on Drug Design, Institute Pasteur, Paris, France November 25 2022
T1  - Identification of novel 1-benzhydryl-piperazine derivatives as Histone Deacetylase inhibitors using Fragment-based drug design strategy
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4951
ER  - 
@misc{
author = "Ružić, Dušan and Ellinger, Bernhard and Đoković, Nemanja and Santibanez, Juan and Ganesan, A. and Pavić, Aleksandar and Srdić Rajić, Tatjana and Petković, Miloš and Nikolić, Katarina",
year = "2022",
publisher = "Institute Pasteur, France",
journal = "Journal Club on Drug Design, Institute Pasteur, Paris, France November 25 2022",
title = "Identification of novel 1-benzhydryl-piperazine derivatives as Histone Deacetylase inhibitors using Fragment-based drug design strategy",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4951"
}
Ružić, D., Ellinger, B., Đoković, N., Santibanez, J., Ganesan, A., Pavić, A., Srdić Rajić, T., Petković, M.,& Nikolić, K.. (2022). Identification of novel 1-benzhydryl-piperazine derivatives as Histone Deacetylase inhibitors using Fragment-based drug design strategy. in Journal Club on Drug Design, Institute Pasteur, Paris, France November 25 2022
Institute Pasteur, France..
https://hdl.handle.net/21.15107/rcub_farfar_4951
Ružić D, Ellinger B, Đoković N, Santibanez J, Ganesan A, Pavić A, Srdić Rajić T, Petković M, Nikolić K. Identification of novel 1-benzhydryl-piperazine derivatives as Histone Deacetylase inhibitors using Fragment-based drug design strategy. in Journal Club on Drug Design, Institute Pasteur, Paris, France November 25 2022. 2022;.
https://hdl.handle.net/21.15107/rcub_farfar_4951 .
Ružić, Dušan, Ellinger, Bernhard, Đoković, Nemanja, Santibanez, Juan, Ganesan, A., Pavić, Aleksandar, Srdić Rajić, Tatjana, Petković, Miloš, Nikolić, Katarina, "Identification of novel 1-benzhydryl-piperazine derivatives as Histone Deacetylase inhibitors using Fragment-based drug design strategy" in Journal Club on Drug Design, Institute Pasteur, Paris, France November 25 2022 (2022),
https://hdl.handle.net/21.15107/rcub_farfar_4951 .

Rational design and in vitro evaluation of selective inhibitors of cytoplasmic histone deacetylases SIRT2 and HDAC6

Ružić, Dušan; Đoković, Nemanja; Petković, Miloš; Gul, Sheraz; Lahtela‐Kakkonen, Maija; Ganesan, A.; Srdić-Rajić, Tatjana; Nikolić, Katarina

(European Federation for Medicinal Chemistry and Chemical Biology (EFMC), 2022)

TY  - CONF
AU  - Ružić, Dušan
AU  - Đoković, Nemanja
AU  - Petković, Miloš
AU  - Gul, Sheraz
AU  - Lahtela‐Kakkonen, Maija
AU  - Ganesan, A.
AU  - Srdić-Rajić, Tatjana
AU  - Nikolić, Katarina
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4763
PB  - European Federation for Medicinal Chemistry and Chemical Biology (EFMC)
PB  - Société de Chimie Thérapeutique (SCT)
C3  - EFMC-ISMC, XXVII EFMC International Symposium on Medicinal Chemistry, Book of Abstracts
T1  - Rational design and in vitro evaluation of selective inhibitors of cytoplasmic histone deacetylases SIRT2 and HDAC6
SP  - 141
EP  - 141
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4763
ER  - 
@conference{
author = "Ružić, Dušan and Đoković, Nemanja and Petković, Miloš and Gul, Sheraz and Lahtela‐Kakkonen, Maija and Ganesan, A. and Srdić-Rajić, Tatjana and Nikolić, Katarina",
year = "2022",
publisher = "European Federation for Medicinal Chemistry and Chemical Biology (EFMC), Société de Chimie Thérapeutique (SCT)",
journal = "EFMC-ISMC, XXVII EFMC International Symposium on Medicinal Chemistry, Book of Abstracts",
title = "Rational design and in vitro evaluation of selective inhibitors of cytoplasmic histone deacetylases SIRT2 and HDAC6",
pages = "141-141",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4763"
}
Ružić, D., Đoković, N., Petković, M., Gul, S., Lahtela‐Kakkonen, M., Ganesan, A., Srdić-Rajić, T.,& Nikolić, K.. (2022). Rational design and in vitro evaluation of selective inhibitors of cytoplasmic histone deacetylases SIRT2 and HDAC6. in EFMC-ISMC, XXVII EFMC International Symposium on Medicinal Chemistry, Book of Abstracts
European Federation for Medicinal Chemistry and Chemical Biology (EFMC)., 141-141.
https://hdl.handle.net/21.15107/rcub_farfar_4763
Ružić D, Đoković N, Petković M, Gul S, Lahtela‐Kakkonen M, Ganesan A, Srdić-Rajić T, Nikolić K. Rational design and in vitro evaluation of selective inhibitors of cytoplasmic histone deacetylases SIRT2 and HDAC6. in EFMC-ISMC, XXVII EFMC International Symposium on Medicinal Chemistry, Book of Abstracts. 2022;:141-141.
https://hdl.handle.net/21.15107/rcub_farfar_4763 .
Ružić, Dušan, Đoković, Nemanja, Petković, Miloš, Gul, Sheraz, Lahtela‐Kakkonen, Maija, Ganesan, A., Srdić-Rajić, Tatjana, Nikolić, Katarina, "Rational design and in vitro evaluation of selective inhibitors of cytoplasmic histone deacetylases SIRT2 and HDAC6" in EFMC-ISMC, XXVII EFMC International Symposium on Medicinal Chemistry, Book of Abstracts (2022):141-141,
https://hdl.handle.net/21.15107/rcub_farfar_4763 .